





Monday 28th August 2023

| MP2 A COMPANISON OF DOSE-RINDING METHOD FOR INCORPORATINO SINGLE-AGENT HISTORICAL DATA INTO COMBINATION TRIAL. MP3 ON THE COMPANISON OF CLASSICAL AND WRAPPED CALCY CIRCLUARS REGESSION IN PATIENTS WITH GASTRIC CARRIOMA MP4 STIMATION OF BETWEEN STUDY VARIANCE IN BRYSTAM META-ANALYSIS. BORROWING INFORMATION FROM EXCLUDED STUDIES MP5 DICCISION-MAKING FRAMINVORKS USING MULTIPLE CORDINATE MP6 RIVARIATE COPULA FOR LET AND RIGHT CENSORING. VALIDATION OF A COMPLEX SURROGATE FOR A TIME-TO-EVENT ENDPOINT GENERAL CONTROL OF THE CRICC CURVE STIMATION MP7 REDUCING THE OVERSTITION IN THE CRICC CURVE STIMATION MP8 CHINARCING THE EFFICIENCY OF PROJECTIVE MARKER ANALYSIS OF LOSD TREATMENT CROSSOVER DATA MP9 MODELING AND ESTIMATION FOR HERARCICAL ORDINAL OUTCOME MP10 META ANALYSIS OF CELL FREE MICHORISTS OF BANK SHEET CANACE RETECTION: CAUSES OF INCONSISTENT FINDINGS MP11 ESTIMATING DEC-MRI KTRANS REPEATABILITY BY META-ANALYSIS OF DATA REDUCE AND ANALYSIS OF DATA REDUCED IN CLINICAL STUDIES MP12 THE ROLE OF QUANTITIATIVE EEG (DEED) IN CLINICAL TRIALS. A METHODOLOGICAL REVIEW MP13 MEDIATION ANALYSIS OF DRESTLY AND ADPRONECTIN IN BRASI CANCER RISK: A NESTED COHORT STUDY IN THE IBISI TRIAL MP14 STAGEORED DIFFERENCE—IN-DIFFERENCES FOR ESTIMATING FEFECTS OF AN ONLINE CONSULTATION SYSTEM ON PRESCRIBING EN FIRE ROLE OF LOBOR MARKET INCOLUSITIES IN PER LANGUAGE FOR THE PRESCRIPT OF INCOME. MP15 CAUSAL EFFECT ANALYSIS ON SPASTICITY PLUS OUTCOMES IN PARTIENTS WITH MULTIPLE SCLEROSIS TO MARKET MODEL AND ANALYSIS ON SPASTICITY PLUS OUTCOMES IN PARTIENTS WITH MULTIPLE SCLEROSIS TO MARKET MODEL AND ANALYSIS ON SPASTICITY PLUS OUTCOMES IN PARTIENTS WITH MULTIPLE SCLEROSIS TO MARKET MODEL AND ANALYSIS ON SPASTICITY PLUS OUTCOMES IN PARTIENTS WITH MULTIPLE SCLEROSIS TO MARKET MODEL AND ANALYSIS OF DRESSITY AND ADPRONECTION FIRE REFERS TO A SINCE AND ANALYSIS OF DRESSITY AND ADDRONECTION FIRE REPORTS OF IN PREPARAGING ON PRESCRIBING MP16 CHE ROLE OF THE RECURSION OF THE PREPARAGING ON THE PRESCRIPT OF THE RESULT OF THE PREPARAG | PRESENTER Mutlu Altuntas Koichi Hashizume Adnan Karaibrahimoglu Muneyori Okita Marie-Karelle RIVIERE Giulia Capitoli Susana Diaz Coto Ryo Emoto Kazuharu Harada Emir Sehovic Nivetha Sridharan Markus Waser Federica Bellerba Kate Ellis Feresa Greco Maria Gueltzow Arasutaka Hasegawa Shaun Hiu Simon Newsome Christian Pipper Giulia Pontali AVIWEN XU Junxian Zhu Jurko Aguirre Aziliz Cottin Elsa COZ Kiang Geng |
|--|--|
| MP2 A COMPARISON OF DOSE-RINDING METHOD FOR INCORPORATING SINGLE-AGENT HISTORICAL DATA INTO COMBINATION TRIAL. MP3 ON THE COMPARISON OF CLASSICAL AND WRAPPED LOCKLYCH CRICULAR REPRESSION IN PATIENTS WITH GASTRIC CARRINDIA. MP4 ESTIMATION OF BETWEEN STUDY VARIANCE IN BAYESIAN META-ANALYSIS. BORROWING INFORMATION FROM EXCLUDED STUDIES. MP5 DICCISION-MAKING FRAMINORIS SING MULTIPLE CORDINATION. MP6 RIVARIATE COPULA FOR LEFT AND BIGHT CRASORING: VALIDATION OF A COMPLEX SURROGATE FOR A TIME-TO-EVENT ENDPOINT. MP7 REDUCING THE OVERSTITING IN THE GROC CURVE ESTIMATION. MP7 REDUCING THE OVERSTITING IN THE GROC CURVE ESTIMATION. MP8 SURRIAGE COPULA FOR LEFT AND EIGHT CRASORING: VALIDATION OF A COMPLEX SURROGATE FOR A TIME-TO-EVENT ENDPOINT. MP9 MODELING AND ESTIMATION FOR HERARCHICAL ORDINAL OUTCOME. MP9 MODELING AND ESTIMATION FOR HERARCHICAL ORDINAL OUTCOME. MP10 META-ANALYSIS OF CELL FREE MICROGINAL FOR HEAVE RESEAT CHAPECE DETECTION: CAUSES OF INCONSISTENT FINDINGS. MP11 ESTIMATING DEE-MIN STRANS REPEATABILITY BY META-ANALYSIS OF DATA FROM 12 CLINICAL STUDIES. MP12 STIMATING DEE-MIN STRANS REPEATABILITY BY META-ANALYSIS OF FOR THE ANALYSIS ON SUBSTITUTE THE REGIS OF IN CURNAL TRIALS. A METHODOLOGICAL REVIEW. MP13 MEDIATION ANALYSIS OF DISSITY AND DIPONECTIN IN BREAST CANCER RISK: A NESTED COHORT STUDY IN THE IBISI TRIAL. MP14 STRANGERED DIFFERENCE—HOPETERS FOR ESTIMATING FFFECTS OF AN ONLINE CONSULTATION SYSTEM ON PRESCRIBING. END STRANS OF THE CONTROLLAR OF THE ANALYSIS ON SYSTEM OF THE ANALYSIS ON SYSTEM CONTROLLAR OF THE ANALYSIS ON SYSTEM CONTROLLAR OF THE ANALYSIS ON SYSTEM OF THE ANALYSI | Koichi Hashizume Adnan Karaibrahimoglu Muneyori Okita Marie-Karelle RIVIERE Giulia Capitoli Susana Diaz Coto Ryo Emoto Kazuharu Harada Emir Sehovic Nivetha Sridharan Markus Waser Federica Bellerba Kate Ellis Teresa Greco Maria Gueltzow Grasutaka Hasegawa Shaun Hiu Simon Newsome Christian Pipper Giulia Pontali Zirunxian Zhu Urko Aguirre Aziliz Cottin |
| MP3 ON THE COMPARISON OF CLASSICAL AND WRAPPED CALICHY CIRCULAR REGRESSION IN PATIENTS WITH GASTRIC CARCINOMA MP4 ESTIMATION OF BETWEEN STUDY VARIABLES IN BAYESIAN META ANALYSIS SORROWING INFORMATION FROM EXCLUDED STUDIES MP5 DICISION-MAKING FRAMEWORKS USING MULTIPLE CORRELATED (INDPOINTS NP6 SIVARIATE COPULA FOR LEFT AND RIGHT CENSORING: VALIDATION OF A COMPLEX SURROGATE FOR A TIME-TO-EVENT ENDPOINT GRAPH CONTINUES OF THE FEFTICENCY OF PREDICTIVE MARKER ANALYSIS SY USING TREATMENT CROSSOVER DATA MP7 REDUCING THE OVERHITTING IN THE GROC CURVE ESTIMATION MP8 EHHANCING THE EFFICIENCY OF PREDICTIVE MARKER ANALYSIS SY USING TREATMENT CROSSOVER DATA MP9 MODELING AND ISTIMATION FOR HEARDHOLD UTCOME MP90 META ANALYSIS OF CELL-FREE MICKORNAS FOR EARLY BREAST CANCER DETECTION: CAUSES OF INCONSISTENT FINDINGS ENTIRE STIMATING CHE MICKORNAS FOR EARLY BREAST CANCER DETECTION: CAUSES OF INCONSISTENT FINDINGS ENTIRE STIMATING CHE MICKORNAS FOR EARLY BREAST CANCER RETECTION: CAUSES OF INCONSISTENT FINDINGS MP10 STIMATING CHE MICKORNAS FOR EARLY BREAST CANCER RETECTION: CAUSES OF INCONSISTENT FINDINGS MP12 THE ROLE OF QUANTITATIVE EEG (QEEG) IN CLINICAL TRUALS: A METHODOLOGICAL REVIEW MP33 MEDIATION AND ANALYSIS OF ORSISTIVA AND ADPROMENTIN IN BREAST CANCER RETECTION: CAUSES OF INCONSISTENT FINDINGS MP14 STAGGERED DIFFERENCE: HOUPERENCES FOR ESTIMATING EFFECTS OF AN ONLINE CONSULTATION SYSTEM ON PRESCRIBING MP15 CAUSE SET OF A SHARP AND ADPROMENTIN IN BREAST CANCER REVIEW MP16 THE ROLE OF LABOR MARKET INEQUALITIES IN EXPLAINING THE GENORE GAP IN DEPRESSION RISK AMMONG QUEE US ADULTS. MP17 DIVIDENDMENT OF ENSIMALE PROPERTIES FOR ESTIMATING EFFECTS OF AN ONLINE CONSULTATION SYSTEM ON PRESCRIBING MP18 INSTRUMENTAL VARIABLES SYSTEMATIC REVIEW OF STRATEGIES TO JUSTIP! VALIDITY IN CLINICAL STUDIES OF DEMENTIA MP19 INSTRUMENTAL VARIABLES SYSTEMATIC REVIEW OF STRATEGIES TO JUSTIP! VALIDITY IN CLINICAL STUDIES OF DEMENTIA MP19 INSTRUMENTAL VARIABLES SYSTEMATIC REVIEW OF STRATEGIES TO JUSTIP! VALIDITY IN CLINICAL STU | Adnan Karaibrahimoglu Muneyori Okita Marie-Karelle RIVIERE Giulia Capitoli Susana Diaz Coto Ryo Emoto Kazuharu Harada Emir Sehovic Nivetha Sridharan Markus Waser Federica Bellerba Kate Ellis Feresa Greco Maria Gueltzow Frasutaka Hasegawa Shaun Hiu Simon Newsome Christian Pipper Giulia Pontali FINNA XU Ilunxian Zhu Urko Aguirre Aziliz Cottin |
| MP4 DESIGNATION OF BETWEEN STUDY VARIANCE IN BAYESIAN META-ANALYSIS: BORROWING INFORMATION FROM EXCLUDED STUDIES MP5 DECISION-MARKING FRAMEWORKS LINKING MULTIPLE CORRELATED INDOPINITS MP6 BIVARIATE COPULA FOR LET AND RIGHT CENSORING: VALIDATION OF A COMPLEX SURROGATE FOR A TIME-TO-EVENT ENDPOINT MP7 REDUCING THE OUTPUT FOR THE FOR CHARKER ANALYSES BY USING TREATMENT CROSSOVER DATA MP8 INHARCING THE EFFICIENCY OF PREDICTIVE MARKER ANALYSES BY USING TREATMENT CROSSOVER DATA MP9 MODELING AND ESTIMATION OF HER PROCECUPIC ESTIMATION MP10 META-ANALYSIS OF CELL-FREE MICRORINAS FOR LARLY BREAST CANCER DETECTION: CAUSES OF INCONSISTENT FINDINGS MP11 STIMATING DCE-MRI KTARAS REPEATABILITY BY META-ANALYSIS OF DATA FROM 12 CLINICAL STUDIES MP12 THE ROLE OF QUANTITATIVE EER (GEGE) IN CLINICAL TRIALS: A METHODOLOGICAR REVIEW MP13 MEDIATION ANALYSIS OF DESTIY AND ADPROMECTIN IN BREAST CANCER RISK AND STREAM THE MEDIATION ANALYSIS OF DESTIY AND ADPROMECTIN IN BREAST CANCER RISK THE META-ANALYSIS OF DATA FROM THE MEDIATION ANALYSIS OF DESTIY AND ADPROMECTIN IN BREAST CANCER RISK AND STREAM THE MEDIATION ANALYSIS OF DESTIY AND ADPROMECTIN IN BREAST CANCER RISK AND STREAM THE MEDIATION ANALYSIS OF DESTIY AND ADPROMECTIN IN BREAST CANCER RISK AND STREAM THE MEDIATION ANALYSIS OF DESTIY AND ADPROMECTIN IN BREAST CANCER RISK AND STREAM THE MEDIATION ANALYSIS OF DESTIY AND ADPROMECTIN IN BREAST CANCER RISK AND STREAM THE MEDIATION ANALYSIS OF DESTIY AND ADPROMECTIVE STREAM THE MEDIATION ANALYSIS OF T | Muneyori Okita Marie-Karelle RIVIERE Giulia Capitoli Susana Diaz Coto Ryo Emoto Kazuharu Harada Emir Sehovic Nivetha Sridharan Markus Waser Federica Bellerba Kate Ellis Feresa Greco Maria Gueltzow Friastaka Hasegawa Shaun Hiu Simon Newsome Christian Pipper Giulia Pontali Friws Ay Luxian Zhu Urko Aguirre Aziliz Cottin Elsa COZ |
| MM6 BINARITAT COPULA FOR LET AND RIGHT CENSORING: VALIDATION OF A COMPLEX SURROGATE FOR A TIME-TO-EVENT ENDPOINT MP7 REDUCING THE OVERTITHING IN THE GROC CURVE SETMATION MP8 ENHANCING THE EFFCIENCY OF PREDICTIVE MARKER ANALYSES BY USING TREATMENT CROSSOVER DATA MP9 MODELING AND ESTIMATION FOR HERARCHICAL ORDINAL OUTCOME MP10 META-ANALYSES OF CELL FREE MICRORRAS FOR EARLY SERSOT CANCER DETECTION: CAUSES OF INCONSISTENT FINDINGS ENHANCING THE REPOLED OF LONGER STRANGE REPORT OF THE REPORT OF THE REPORD OF LONGER STRANGE OF THE REPORT OF TH | Giulia Capitoli Susana Diaz Coto Ryo Emoto Kazuharu Harada Emir Sehovic Nivetha Sridharan Markus Waser Federica Bellerba Kate Ellis Feresa Greco Maria Gueltzow Fasutaka Hasegawa Shaun Hiu Simon Newsome Christian Pipper Giulia Pontali FriWEN XU Junxian Zhu Jrko Aguirre Aziliz Cottin Elsa COZ |
| MP7 REDUCING THE OVERRETTING IN THE GROC CURVE ESTIMATION MP8 ENHANCING THE EFFICIENCY OF PREDICTIVE MARKER ANALYSES BY USING TREATMENT CROSSOVER DATA MP9 MODELING AND ESTIMATION FOR HIERARCHICAL ODDINAL OUTCOME MP10 META-ANALYSIS OF CELL-REE MICRORNAS FOR EARLY BREAST CANCER DETECTION: CAUSES OF INCONSISTENT FINDINGS IN MP11 META-ANALYSIS OF CELL-REE MICRORNAS FOR EARLY BREAST CANCER DETECTION: CAUSES OF INCONSISTENT FINDINGS IN MP12 THE ROLE OF QUANTITATIVE EEG (DEEG) IN CUINICAL TRIALS: A METHODOLOGICAL REVIEW IN MP13 MEDITION ANALYSIS OF OBESITY AND ADIPOPMENT IN BREAST CANCER REVIEW IN MP14 STAGGERED DIFFERENCE: NO. BESTIMATING EFFECTS OF AN ONLINE CONSULTATION SYSTEM ON PRESCRIBING IN MP15 STAGGERED DIFFERENCE: NO. BESTIMATING EFFECTS OF AN ONLINE CONSULTATION SYSTEM ON PRESCRIBING IN MP16 THE ROLE OF LABOR MARKET IN EQUALITIES IN EXPLAIMING THE GRIDER GAP IN DEPRESSION RISK AMONG CLDER US ADULTS. IN MP16 THE ROLE OF LABOR MARKET IN EQUALITIES IN EXPLAIMING THE GRIDER GAP IN DEPRESSION RISK AMONG CLDER US ADULTS. IN MP17 DEVELOPMENT OF ERSKMILE PROPENTYS SCORE MARKETING HIGH MARKETING AND ADULTS. IN MP18 INSTRUMENTAL VARIABLES: SYSTEMATIC REVIEW OF STRATEGIES TO JUSTIFY VALIDITY IN CLINICAL STUDIES OF DEMENTIA. IN MP19 APPLYING CAUSAL INFERENCE TO CLINICAL TRIAL DATA TO IMPROVE OUR UNDERSTANDING OF HOW CART CELL THERAPIES WORK IN MP20 UNBASED AND EFFICIENT ESTIMATION OF CAUSAL TREATMENT FEFECTS IN CROSS-OVER TRIALS COMBINING DATASETS IN A MENDELIAN RANDOMIZATION DESIGN. METABOLOMICS AND PARKINSON'S DISASE CASE TUDY IN MP22 TRIAL EMULLATION FOR GROUP POLICIES: IMPACT OF OUNINE CONSULTATION SYSTEM ON ERROGENCY HOSTAGE OF MULTI-STATE MODELS IN MP22 TRIAL EMULLATION FOR ROUP POLICIES: IMPACT OF OUNINE CONSULTATION SYSTEM ON ERROGENCY HOSTAGE OR MULTI-STATE MODELS IN MP23 ACCOUNTING FOR NON-COMPLIANCE WHEN ESTIMATING THEATMENT EFFECTS OF ORDINAL OUTCOME IN RCT IN MP24 AS ACCOUNTING FOR NON-COMPLIANCE WHEN ESTIMATING THEATMENT EFFECTS OF ORDINAL OUTCOME IN RCT IN MP25 AND STRATE AND ADMITTAT | Susana Diaz Coto Ryo Emoto (azuharu Harada Emir Sehovic Nivetha Sridharan Markus Waser Federica Bellerba (ate Ellis Teresa Greco Maria Gueltzow //asutaka Hasegawa shaun Hiu Simon Newsome Christian Pipper Giulia Pontali //INEN XU Junxian Zhu Jrko Aguirre Aziliz Cottin |
| MPB ENHANCING THE EFFICIENCY OF PREDICTIVE MARKER ANALYSES BY USING TREATMENT CROSSOVER DATA MPB MODELING AND ESTIMATION FOR LARRACHERA CORDINAL OUTCOME MP10 META-ANALYSIS OF CELL FREE MICKORNAS FOR EARLY BREAST CANCER DETECTION: CAUSES OF INCONSISTENT FINDINGS RM111 ESTIMATING DEC-MIN KTRANS REPEATABILITY BY META-ANALYSIS OF DATA FROM 12 CLINICAL STUDIES NM1912 THE ROLE OF QUANTITATIVE EQ (DEEG) IN CLINICAL STUDIES NM1913 MEDIATION ANALYSIS OF OBESITY AND ADIPONECTIN IN BREAST CANCER RISK: A NESTED-COHORT STUDY IN THE IBISI TRIAL FINDING MIPS AND ANALYSIS OF OBESITY AND ADIPONECTIN IN BREAST CANCER RISK: A NESTED-COHORT STUDY IN THE IBISI TRIAL FINDING MIPS AND ANALYSIS OF OBESITY AND ADIPONECTIN IN BREAST CANCER RISK: A NESTED-COHORT STUDY IN THE IBISI TRIAL FINDING MIPS AND ANALYSIS OF OBESITY AND ADIPONECTIN IN BREAST CANCER RISK: A NESTED-COHORT STUDY IN THE IBISI TRIAL FINDING MIPS AND ANALYSIS OF OBESITY AND ADIPONECTIN IN BREAST CANCER RISK: A NESTED-COHORT STUDY IN THE IBISI TRIAL FINDING MIPS AND | Ryo Emoto Kazuharu Harada "mir Sehovic Nivetha Sridharan Markus Waser Federica Bellerba Kate Ellis Feresa Greco Maria Gueltzow Arasutaka Hasegawa Shaun Hiu Simon Newsome Christian Pipper Giulia Pontali Ariwen XU Junxian Zhu Jrko Aguirre Aziliz Cottin Elsa COZ |
| MP9 MODELING AND ESTIMATION FOR HIERARCHICAL ORDINAL OUTCOME MP10 META-ANALYSIS OF CELL-FREE MICRORNAS FOR EARLY BREAST CANCER DETECTION: CAUSES OF INCONSISTENT FINDINGS RP11 ESTIMATING DEC-MINI KITRANS REPEATABILITY BY META-ANALYSIS OF DATA FROM 12 CLINICAL STUDIES N MP12 THE ROLE OF QUANTITATIVE EEG (GLEEG) IN CLINICAL TRIALS: A METHODOLOGICAL REVIEW M MP13 MEDIATION ANALYSIS OF DESTIYA AND ADIPONECTINE BREAST CAMBER SIKE: A NESTED COHORT STUDY IN THE IBISII TRIAL RP14 STAGGERED DIFFERENCE-IN-DIFFERENCES FOR ESTIMATING EFFECTS OF AN ONLINE CONSULTATION SYSTEM ON PRESCRIBING RP15 CAUSAL EFFECT ANALYSIS ON SPRETICITY-PULS OUTCOMES IN PATENTS WITH MULTIPLE SCLEROSS T TO MP16 THE ROLE OF LABOR MARKET INEQUALITIES IN EVPLAINING THE GENDER GAP IN DEPRESSION RISK AMONG OLDER US ADULTS. MP16 THE ROLE OF LABOR MARKET INEQUALITIES IN EVPLAINING THE GENDER GAP IN DEPRESSION RISK AMONG OLDER US ADULTS. MP17 DEVELOPMENT OF ENSEMBLE PROPENSITY SCORE MATCHINE METHOD MP18 INSTRUMENTAL VARIBABLES: VSYTEMATIC REVIEW OF STRATEGIES TO JUSTIEY VALIDITY IN CLINICAL STUDIES OF DEMENTIA MP19 APPLYING CAUSAL INFERENCE TO CLINICAL TRAIL DATA TO IMPROVE OUR UNDERSTANDING OF HOW CART-T CELL THERAPIES WORK MP20 LONDING OR DEFFICIENT ESTIMATION OF CAUSAL TREATMENT EFFECTS IN CROSS-OVER TRIALS C COMBINING DATASETS IN A MENDELIAN RANDOMIZATION DISSION. METABOLOMICS AND PARRINSON'S DISEASE CASE STUDY MP21 COMBINING DATASETS IN A MENDELIAN RANDOMIZATION DISSION. METABOLOMICS AND PARRINSON'S DISEASE CASE STUDY MP22 ACCOUNTING FOR NON-COMPLIANCE WHEN ESTIMATING TREATMENT EFFECTS OF ORDINAL OUTCOME IN RCT JAMP24 RISK FACTORS FOR THE SURVIVAL OF COUNTER-RACTUAL PERTURBATION FEATURE IMPORTANCE FOR MULTI-STATE MODELS MP23 ACCOUNTING FOR NON-COMPLIANCE WHEN ESTIMATING TREATMENT EFFECTS OF ORDINAL OUTCOME IN RCT JAMP24 SHE SHE DETERMINATION BASED ON RESTRICTED MEAN TIME LOST IN THE PRESENCE OF COMPETING RISKS MP26 SHE PAGE AND ADDITION OF STATE AND ADDITION STATE OF THE WAS ANALYSIS. UN MP27 SHE PAGE AND ADDITION OF STATE AND ADDI | Cazuharu Harada Emir Sehovic Viivetha Sridharan Markus Waser Federica Bellerba Kate Ellis Feresa Greco Maria Gueltzow Frasutaka Hasegawa Shaun Hiu Simon Newsome Christian Pipper Giulia Pontali FIWEN XU Junxian Zhu Jurko Aguirre Aziliz Cottin |
| MP10 META-ANALYSIS OF CELL-FREE MICRORIANS FOR EARLY BREAST CANCER DETECTION: CAUSES OF INCONSISTENT FINDINGS MP11 ESTIMATING DCE-MRI KTRANS REPEATABILTY BY META-ANALYSIS OF DATA FROM 12 CLINICAL STUDIES NP18 STEP AND | Emir Sehovic Nivetha Sridharan Markus Waser Federica Bellerba Kate Ellis Feresa Greco Maria Gueltzow fasutaka Hasegawa Shaun Hiu Simon Newsome Christian Pipper Giulia Pontali r/WEN XU Junxian Zhu Jrko Aguirre Aziliz Cottin Elsa COZ |
| MP11 ESTIMATING DCC-MRI KTRANS REPEATABILITY BY META-ANALYSIS OF DATA FROM 12 CLINICAL STUDIES MP22 THE ROLE OF QUANTITATIVE EEG (QEEG) IN CLINICAL TRIALS: A METHODOLOGICAL REVIEW MP34 STAGGERED DIFFERENCE: IN-DIFFERENCES FOR ESTIMATING EFFECTS OF AN ONLINE CONSULTATION SYSTEM ON PRESCRIBING RP34 STAGGERED DIFFERENCE: IN-DIFFERENCES FOR ESTIMATING EFFECTS OF AN ONLINE CONSULTATION SYSTEM ON PRESCRIBING RP35 CAUSAL EFFECT ANALYSIS ON SPASTICITY-PLUS QUICKOMES IN PATHOTIS WITH MULTIPLE SCLEROSIS TAMP16 THE ROLE OF LABOR MARKET INEQUALITIES IN EXPLAINING THE GENDER GAP IN DEPRESSION RISK AMONG OLDER US ADULTS. MP16 THE ROLE OF LABOR MARKET INEQUALITIES IN EXPLAINING THE GENDER GAP IN DEPRESSION RISK AMONG OLDER US ADULTS. MP17 DEVELOPMENT OF ENSEMBLE PROPENSITY SCORE MATCHING METHOD MP18 INSTRUMENTAL VARIABLES: SYSTEMATIC REVIEW OF STRATEGIES TO JUSTIFY VALIDITY IN CLINICAL STUDIES OF DEMENTIA MP19 DEVELOPMENT OF ENSEMBLE ROPENSITY SCORE MATCHING METHOD MP19 INSTRUMENTAL VARIABLES: SYSTEMATIC REVIEW OF STRATEGIES TO JUSTIFY VALIDITY IN CLINICAL STUDIES OF DEMENTIA MP20 UNBASED AND EFFICIENT ESTIMATION OF CAUSAL TREATMENT EFFECTS IN CROSS-OVER TRAILS MP21 COMBINING DATASETS IS A MENDELIAN RANDOMIZATION DESIGN: METABOLOMICS AND PARKINSON'S DISEASE EAST DY MP22 THAT EMULATION FOR GROUP POLICIES: IMPACT OF ONLINE CONSULTATION SYSTEM ON EMERGENCY HOSPITAL UTILISATION MP23 ACCOUNTING FOR NON-COMPILANCE WHEN ESTIMATING TREATMENT EFFECTS OF ORDINAL DUTCOME IN RET MP24 RISK FACTORS FOR THE SURVIVAL OF COLORECTAL CANCER PATENTS MODELED THROUGH A COMPETITIVE RISK ANALYSIS. UMP25 MS-CPPI: A MODEL-AGNOSTIC INTERPRETABLE COUNTERPACTUAL PERTURBATION FEATURE IMPORTANCE FOR MULTI-STATE MODELS MP26 MS-CPPI: A MODEL-AGNOSTIC INTERPRETABLE COUNTERPACTUAL PERTURBATION FEATURE IMPORTANCE FOR MULTI-STATE MODELS MP27 SAMPLE SIZE DETERMINATION BASED ON RESTRICTED MEAN TIME LOST IN THE PRESENCE OF COMPETING RISKS MP28 USING MULTISTATE MODELS TO EXPLORE SOCIODEMOGRAPHIC INEQUALITIES IN THE RISK OF ADVERSE PREGNANCY OUTCOM | Nivetha Sridharan Markus Waser Federica Bellerba Kate Ellis Feresa Greco Maria Gueltzow Fasutaka Hasegawa Shaun Hiu Simon Newsome Christian Pipper Siulia Pontali FilwEN XU Junxian Zhu Jrko Aguirre Aziliz Cottin |
| MP12 THE ROLE OF QUANTITATIVE EEG (QEEG) IN CLINICAL TRIALS: A METHODOLOGICAL REVIEW MP13 MEDIATION ANALYSIS OF OBESTY AND ADIPONECTIN IN BREAST CANCER RISKS: A RISETED-CHORT STUDY IN THE IBISII TRIAL F. MP14 STAGGERED DIFFERENCE-IN-DIFFERENCES FOR ESTIMATING EFFECTS OF AN ONLINE CONSULTATION SYSTEM ON PRESCRIBING MP15 CAUSAL EFFECT ANALYSIS ON SPASTICITY-PULS OUTCOMES IN PATIENTS WITH MULTIPLE SCLEROSIS THE ROLE OF LABOOM MARKET INEQUALITIES IN EXPLAINING THE GENDER GAP IN DEPRESSION RISK AMONG OLDER US ADULTS. N. MP17 DEVELOPMENT OF ENSEMBLE PROPENSITY SCORE MATCHING METHOD MP19 INSTRUMENTAL VARIABLES: SYSTEMATIC REVIEW OF STRATEGIES TO JUSTIEY VALIDITY IN CLINICAL STUDIES OF DEMENTIA MP19 APPLYING CAUSAL INFERENCE TO CLINICAL TRIAL DATA TO IMPROVE OUR UNDERSTANDING OF HOW CAR-T CELL THERAPIES WORK MP19 APPLYING CAUSAL INFERENCE TO CLINICAL TRIAL DATA TO IMPROVE OUR UNDERSTANDING OF HOW CAR-T CELL THERAPIES WORK MP20 UNBIASED AND EFFICIENT ESTIMATION OF CAUSAL TREATMENT EFFECTS IN CROSS OVER TRIALS COMBINING DATASETS IN A MENDELIAN RANDOMIZATION DESIGN. METABOLOMICS AND PARISINSON'S DISEASE CASE STUDY G MP21 TRIAL EMULATION FOR GROUP POLICIES: IMPACT OF ONLINE CONSULTATION SYSTEM ON EMBRISHED AND ANALYSIS. MP22 RICE OF NON-COMPLICACE WHAT ENTIRATING THE FETCH OF ORDINAL OUTCOME IN RCT JAMP24 RISK FACTORS FOR THE SURVIVAL OF COLORECTAL CANCER PATIENTS MODELED THROUGH A COMPETITIVE RISK ANALYSIS. UM25 MSC-SPIT: A MODEL-AGNOSTIC INTERPRETABLE COUNTERFACTULAL PERTURBATION FOR MULTI-STATE MODELS A PAPE SHAPPE SHAPPOLE-AGNOSTIC INTERPRETABLE COUNTERFACTULAL PERTURBATION FOR FAUTH STATE MODELS A PAPE SHAPPE SHAPPOLE-AGNOSTIC INTERPRETABLE COUNTERFACTULAL PERTURBATION FOR BUTHLY STATE MODELS A PAPE SHAPPOLE-AGNOSTIC INTERPRETABLE COUNTERFACTULAL PERTURBATION FOR BUTHLY STATE MODELS A PAPE SHAPPOLE AGNOSTIC STATE PREPATED THE OUTCOMES FOR THE SURVIVAL OF COLORECTAL CANCER PATIENTS MODELED THROUGH A COMPETITIVE RISK ANALYSIS. MP28 SHAPPE SIZE DETERMINATION BASED ON RESTRICTED MEAN TIME LOST IN THE PRESSECE OF COMPETIN | Federica Bellerba (Ate Ellis Teresa Greco Maria Gueltzow //asutaka Hasegawa Shaun Hiu Simon Newsome Christian Pipper Giulia Pontali ///unxian Zhu Urko Aguirre Aziliz Cottin |
| MP14 STAGGERED DIFFERENCE IN-DIFFERENCES FOR ESTIMATING EFFECTS OF AN ONLINE CONSULTATION SYSTEM ON PRESCRIBING MP15 CAUSAL EFFECT ANALYSIS ON SPASTICITY-PLUS OUTCOMES IN PATIENTS WITH MULTIPLE SCLEROSIS TO MP16 THE ROLG OF LABOR MARKET INFOQUALITIES IN BEXPLAINING THE GENDER GAP IN DEPRESSION RISK AMONG OLDER US ADULTS. N MP17 DEVELOPMENT OF ENSEMBLE PROPENSITY SCORE MATCHING METHOD MP18 IN INSTRUMENTAL VARIABLES: SYSTEMATIC REVIEW OF STRATTGESTS TO JUSTIEVY VALIDITY IN CLINICAL STUDIES OF DEMENTIA MP19 APPLYING CAUSAL INFERENCE TO CLINICAL TRIAL DATA TO IMPROVE OUR UNDERSTANDING OF HOW CAR-T CELL THERAPIES WORK MP20 UNBIASED AND EFFICIENT ESTIMATION OF CAUSAL TREATMENT EFFECTS IN CROSS-OVER TRIALS COMBINING DATASETS IN A MENDELLAN RANDOMIZATION DESIGN. METABOLOMICS AND PARKINSON'S DISEASE CASE STUDY GENERAL COMBINING DATASETS IN A MENDELLAN RANDOMIZATION DESIGN. METABOLOMICS AND PARKINSON'S DISEASE CASE STUDY GENERAL COMBINING DATASETS IN A MENDELLAN RANDOMIZATION DESIGN. METABOLOMICS AND PARKINSON'S DISEASE CASE STUDY GENERAL COMBINING DATASETS IN A MENDELLAN RANDOMIZATION DESIGN. METABOLOMICS AND PARKINSON'S DISEASE CASE STUDY GENERAL COLOR OF THE SURVIVAL OF COLORECTAL CANCER PATIENTS MODELED THROUGH A COMPETITIVE RISK ANALYSIS. UNP22 THALE MULLATION FOR GROUP POLICIES: IMPACT OF ONLINE CONSULTATION SYSTEM ON EMERGENCY HOSPITAL UTILISATION MP24 RISK FACTORS FOR THE SURVIVAL OF COLORECTAL CANCER PATIENTS MODELED THROUGH A COMPETITIVE RISK ANALYSIS. UNP25 MS-CPI: A MODEL-AGNOSTIC INTERPRETABLE COUNTERFACTUAL PERTURDAT FROM THE IMPORTANCE FOR MULTI-STATE MODELS MP26 MS-CPI: A MODEL-AGNOSTIC INTERPRETABLE COUNTERFACTUAL PERTURDAT FROM THE IMPORTANCE FOR MULTI-STATE MODELS MP27 SAMPLE SUZE DETERMINATION ON ASSED ON RESTRICTED MEAN THRE LOST IN THE PRESENCE OF COMPETING RISKS MP28 LEVIBLE LOST OF THE SURVIVAL OF COLORECTAL CANCER PATIENTS MODELED THROUGH A COMPETITIVE RISK ANALYSIS. MP29 USING MULTISTATE MODELS TO EXPENSE OVER SOME AND THRE THE OFFICE AND THRE THE THRE THE OWN THRE THE THRE THE OWN THRE THE TH | Kate Ellis Feresa Greco Maria Gueltzow Frasutaka Hasegawa Shaun Hiu Simon Newsome Christian Pipper Giulia Pontali FIWEN XU Iunxian Zhu Urko Aguirre Aziliz Cottin |
| MP15 CAUSAL EFFECT ANALYSIS ON SPASTICITY-PLUS OUTCOMES IN PATIENTS WITH MULTIPLE SCLEROSIS MP16 THE ROLE OF LABOR MARKET INEQUALITIES IN EXPLAINING THE GENDER GAP IN DEPRESSION RISK AMONG OLDER US ADULTS. MP17 THE ROLE OF LABOR MARKET INEQUALITIES IN EXPLAINING THE GENDER GAP IN DEPRESSION RISK AMONG OLDER US ADULTS. MP18 INSTRUMENTAL VARIABLES: SYSTEMATIC REVIEW OF STRATEGIES TO JUSTIEY VALIDITY IN CLINICAL STUDIES OF DEMENTIA MP19 APPLYING CAUSAL INFERENCE TO CLINICAL THAIL DATA TO IMPROVE OUR UNDERSTANDING OF HOW CART CELL THERAPIES WORK MP20 UNBIASED AND EFFICIENT ESTIMATION OF CAUSAL TREATMENT EFFECTS IN CROSS-OVER TRIALS COMBINING DATASETS IN A MENDELIAN RANDOMIZEATION DESIGN: METABOLOMICS AND PARKINSON'S DISEASE CASE STUDY MP21 COMMINING DATASETS IN A MENDELIAN RANDOMIZEATION DESIGN: METABOLOMICS AND PARKINSON'S DISEASE CASE STUDY MP22 TRIAL EMULATION FOR GROUP POLICIES: IMPACT OF ONLINE CONSULTATION SYSTEM ON EMERGENCY HOSPITAL UTILISATION MP23 ACCOUNTING FOR NON-COMPLIANCE WHEN ESTIMATING TREATMENT EFFECTS OF ORBINAL OUTCOME IN RCT MP24 RISK FACTORS FOR THE SURVIVAL OF COLORECTAL CANCER PATIENTS MODELED THROUGH A PROPERTIVE SK ANALYSIS. UMP25 MS-CPPI: A MODEL-AGNOSTIC INTERPRETABLE COUNTERFACTULAL PERTURBATION FEATURE IMPORTANCE FOR MULTI-STATE MODELS MS-CPPI: A MODEL-AGNOSTIC INTERPRETABLE COUNTERFACTULAL PERTURBATION FEATURE IMPORTANCE FOR MULTI-STATE MODELS MP26 FLEXIBLE LOG-HAZARD MODEL FOR ADVERSE EVENTS ANALYSIS. MP27 SAMPLE SIZE DETERMINATION BASED ON RESTRICTED MEAN TIME LOST IN THE PRESENCE OF COMPETING RISKS MP29 LUSING MULTISTATE MODELS TO EXPLORE SOCIOEMOGRAPHIC INEQUALITIES IN THE RISK OF A DVERSE PREGNANCY OUTCOMES MP30 HOW REFUNDATION AND THE METABOLOR MULTI-MORBIDITY MP31 LUSING MULTISTATE MODELS TO EXPLORE SOCIOEMOGRAPHIC INEQUALITIES IN THE RISK OF A DVERSE PREGNANCY OUTCOMES MP32 LUSING MULTISTATE MODELS TO EXPLORE SOCIOEMOGRAPHIC INEQUALITIES IN THE RISK OF A DVERSE PREGNANCY OUTCOMES MP33 DETERMINANTS OF VACCINE INTENTION AGAINST COUNT-19 FADRESIC INTO A DVERSE | Feresa Greco Maria Gueltzow /asutaka Hasegawa Shaun Hiu Simon Newsome Christian Pipper Giulia Pontali //IWEN XU lunxian Zhu Jrko Aguirre Aziliz Cottin |
| MP16 THE ROLE OF LABOR MARKET INEQUALITIES IN EXPLAINING THE GENDER GAP IN DEPRESSION RISK AMONG OLDER US ADULTS. MP17 DEVELOPMENT OF ENSEMBLE ROPPENSITY SCORE MATCHING METHOD Y. MP18 INSTRUMENTAL VARIABLES: SYSTEMATIC REVIEW OF STRATEGIES TO JUSTIEY VALIDITY IN CLINICAL STUDIES OF DEMENTIA MP19 APPLYING CAUSAL INFERENCE TO CLINICAL TRIAL DATA TO IMPROVE OUR UNDERSTANDING OF HOW CART CELL THERAPIES WORK S. MP20 UNBIASED AND EFFICIENT ESTIMATION OF CAUSAL. TREATMENT EFFECTS IN CROSS-OVER TRIAL DATA TO IMPROVE OUR UNDERSTANDING OF HOW CART CELL THERAPIES WORK MP21 COMBINING DATASETS IN A MENDELIAN RANDOMIZATION DESIGN: METABOLOMICS AND PARKINSON'S DISEASE CASE STUDY G. MP22 TRIAL EMULATION FOR GROUP POLICIES: IMPACT OF ONLINE CONSULTATION SYSTEM ON EMERGENCY HOSPITAL UTILISATION MP23 TRIAL EMULATION FOR GROUP POLICIES: IMPACT OF ONLINE CONSULTATION SYSTEM ON EMERGENCY HOSPITAL UTILISATION MP24 RISK FACTORS FOR THE SURVIVAL OF COLORECTAL CANCER PATIENTS MODELED THROUGH A COMPETITIVE RISK ANALYSIS. UMP25 MS-CPFI: A MODEL-AGNOSTIC INTERPRETABLE COUNTERFACTUAL PERTURBATION FEATURE IMPORTANCE FOR MULTI-STATE MODELS MP26 FLEMBLE LOG-HAZARD MODEL FOR ADVERSE EVENTS ANALYSIS. MP27 SAMPLE SIZE DETERMINATION BASED ON RESTRICTED MEAN TIME LOST IN THE PRESENCE OF COMPETING RISKS MP28 HANDLING MISSING DISEASE INFORMATION IN DISEASES THAT NEED TWO VISTS TO DIAGNOSE MP29 USING MULTISTATE MODELS TO EXPLORE SOCIODEMOGRAPHIC INCQUALITIES IN THE RISK OF ADVERSE PREGNANCY OUTCOMES MP30 HOW RHEUMATOID ARTHRITIS DISEASE ACTIVITY AFFECTS THE RISK OF CARDIOVASCULAR MULTIMORBIDITY MP31 RESTRICTED MEAN TIME LOST MODEL FOR COVARIATES WITH TIME-VARYING EFFECTS MP32 COVID-19 INFECTION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN CHINA: MILD CLINICAL COURSE MP31 DETERMINANTS OF VACCINE INTENTION AGAINST COVID-19 S. ASERIAL MEDIATION APPROACH MP33 DETERMINANTS OF VACCINE INTENTION AGAINST COVID-19 S. ASERIAL MEDIATION APPROACH MP34 SOCIAL ISOLATION AND MENTAL HEALTH OF OLDER CITIZENS DURING THE COVID-19 PANDEMIC AMP30 D | Maria Gueltzow /fasutaka Hasegawa Shaun Hiu Simon Newsome Christian Pipper Giulia Pontali //WEN XU lunxian Zhu Urko Aguirre Aziliz Cottin |
| MP17 DEVELOPMENT OF ENSEMBLE PROPENSITY SCORE MATCHING METHOD MP18 INSTRUMENTAL VARIABLES: SYSTEMATIC REVIEW OF STRATEGIES TO JUSTIFY VALIDITY IN CLINICAL STUDIES OF DEMENTIA SYMP19 APPLYING CAUSAL INFERENCE TO CLINICAL TRIAL DATA TO UMPROVE OUR UNDERSTANDING OF HOW CAR-T CELL THERAPIES WORK SYMP20 UNBIASED AND EFFICIENT ESTIMATION OF CAUSAL TREATMENT EFFECTS IN CROSS-OVER TRIALS COMBINING DATASETS IN A MENDELIAN RANDOMIZATION DESIGN: METABOLOMICS AND PARKINSON'S DISEASE CASE STUDY MP21 COMBINING DATASETS IN A MENDELIAN RANDOMIZATION DESIGN: METABOLOMICS AND PARKINSON'S DISEASE CASE STUDY MP22 TRIAL EMULATION FOR GROUP POLICIES: IMPACT OF ONLINE CONSULTATION SYSTEM ON PARKINSON'S DISEASE CASE STUDY MP23 ACCOUNTING FOR NON-COMPULANCE WHEN ESTIMATING TREATMENT EFFECTS OF ORDINAL OUTCOME IN RCT MP24 RISK PACTORS FOR THE SURVIVAL OF COLORECTAL CANCER PATIENTS MODELED THROUGH A COMPETITIVE RISK ANALYSIS. MP25 MS-CPFI: A MODEL-AGNOSTIC INTERPRETABLE COUNTERFACTUAL PERTURBATION FEATURE IMPORTANCE FOR MULTI-STATE MODELS MP26 FLEXIBLE LOG-HAZARD MODEL FOR ADVERSE EVENTS ANALYSIS MP27 SAMPLE SIZE DETERMINATION BASED ON RESTRICTED MEAN TIME LOST IN THE PRESENCE OF COMPETING RISKS X PAP28 HANDLING MISSING DISEASE INFORMATION IN DISEASES THAT INEED TWO MISSTS TO DIAGNOSE MP29 USING MULTISTATE MODELS TO EXPLORE SOCIODEMOGRAPHIC INEQUALITIES IN THE RISK OF ADVERSE PREGNANCY OUTCOMES MP30 HOW RHEUMATOID ARTHRITIS DISEASE ACTIVITY AFFECTS THE RISK OF CARDIOVASCULAR MULTIMORBIDITY LIMPASE COVID-19 HENCETON IN CHILDREN WITH A CIVIL ELYMPHOBIANTIC INFOUNDATION AND PROACH MP31 RESTRICTED MEAN TIME LOST MODEL FOR COVARIATES WITH TIME-VARYING EFFECTS MP32 COVID-19 HENCETON IN CHILDREN WITH ACIDIT ELYMPHOBIANTIC INFOUNDATION AND PROACH MP34 SOCIAL ISOLATION AND MENTAL HEALTH OF OLDER CITIZENS DURING THE COVID-19 PANDEMIC AP35 COVID-19 HENCETON IN CHILDREN WITH ACIDIT ON DURING THE COVID-19 PANDEMIC AP36 SOCIAL ISOLATION AND MENTAL HEALTH OF OLDER CITIZENS DURING THE COVID-19 PANDEMIC AP37 USEFULIAL THE PRESENCE OF | rasutaka Hasegawa Shaun Hiu Simon Newsome Christian Pipper Giulia Pontali riWEN XU lunxian Zhu Urko Aguirre Aziliz Cottin |
| MP18 INSTRUMENTAL VARIABLES: SYSTEMATIC REVIEW OF STRATEGIES TO JUSTIFY VALIDITY IN CLINICAL STUDIES OF DEMENTIA MP19 APPLYING CAUSAL INFERENCE TO CLINICAL TRIAL DATA TO IMPROVE OUR NUNBESTANDING OF HOW CAR-T CELL THERAPIES WORK SOUNDISSED AND EFFICIENT ESTIMATION OF CAUSAL TREATMENT EFFECTS IN CROSS-OVER TRIALS COMBINING DATASETS IN A MENDELIAN RANDOMIZATION DESIGN: METABOLOMICS AND PARKINSON'S DISEASE CASE STUDY G MP21 COMBINING DATASETS IN A MENDELIAN RANDOMIZATION DESIGN: METABOLOMICS AND PARKINSON'S DISEASE CASE STUDY G MP22 TRIAL EMULATION FOR GROUP POLICIES: IMPACT OF ONLINE CONSULTATION SYSTEM ON EMERGENCY HOSPITAL UTILISATION MP23 ACCOUNTING FOR NON-COMPLIANCE WHEN ESTIMATING TREATMENT EFFECTS OF ORDINAL OUTCOME IN RCT ACCOUNTING FOR NON-COMPLIANCE WHEN ESTIMATING TREATMENT EFFECTS OF ORDINAL OUTCOME IN RCT ACCOUNTING FOR NON-COMPLIANCE WHEN ESTIMATING TREATMENT EFFECTS OF ORDINAL OUTCOME IN RCT ACCOUNTING FOR NON-COMPLIANCE WHEN ESTIMATING TREATMENT BEFECTS OF ORDINAL OUTCOME IN RCT ACCOUNTING FOR NON-COMPLIANCE WHEN ESTIMATING TREATMENT MEDITIVE BINDORTANCE FOR MULTI-STATE MODELS ACCOUNTING FOR THE SURVIVAL OF COLORECTAL CANCER PATIENTS MODELED THROUGH A COMPETTIVE RISK ANALYSIS. UNP26 FLEXIBLE LOG-HAZARD MODEL FOR ADVERSE EVENTS ANALYSIS BYP27 SAMPLES SIZE DETERMINATION BASED ON RESTRICTED MEAN TIME LOST IN THE PRESENCE OF COMPETING RISKS XMP28 HANDLING MISSING DISEASE INFORMATION IN DISEASES THAT NEED TWO VISITS TO DIAGNOSE MP29 USING MULTISTATE MODELS TO EXPLORE SOCIODEMOGRAPHIC INEQUALITIES IN THE RISK OF ADVERSE PREGNANCY OUTCOMES MP30 HOW RHEUMATOD ARTHRITIS DISEASE ACTIVITY AFFECTS THE RISK OF CADERIOWASCULAR MULTIMORBIDITY LMP31 RESTRICTED MEAN TIME LOST MODEL FOR COVARIATES WITH TIME-VARYING EFFECTS MP32 COUNTING TO A COUNTING STATE MODELS TO EXPLOYED AND ADMINIST COUNTING STATE RISK OF CADENOS AND AUTOMATIC REVIEW MP31 RESTRICTED MEAN TIME LOST MODEL FOR COVARIATES WITH TIME-VARYING EFFECTS MP32 COUNTING TO ADMINIST OVER COUNTING AFFECTS AS SERIAL MEDITATION AND ADMINI | Shaun Hiu Simon Newsome Christian Pipper Siulia Pontali VIWEN XU Iunxian Zhu Jrko Aguirre Aziliz Cottin |
| MP19 APPLYING CAUSAL INFERENCE TO CLINICAL TRIAL DATA TO IMPROVE OUR UNDERSTANDING OF HOW CAR-T CELL THERAPIES WORK MP20 UNBIASED AND EFFICIENT ESTIMATION OF CAUSAL TREATMENT EFFECTS IN CROSS-OVER TRIALS C OMBINING DATASETS IN A MENDELIAN RANDOMIZATION DESIGN: METABOLOMICS AND PARKINSON'S DISEASE CASE STUDY MP21 TRIAL EMULATION FOR GROUP POLICIES: IMPACT OF ONLINE CONSULTATION SYSTEM ON EMERGENCY HOSPITAL UTILISATION MP23 ACCOUNTING FOR NON-COMPLIANCE WHEN ESTIMATING TREATMENT EFFECTS OF ORDINAL COMMENTATION SYSTEM ON EMERGENCY HOSPITAL UTILISATION MP24 RISK FACTORS FOR THE SURVIVAL OF COLORECTAL CANCER PATIENTS MODELED THROUGH A COMPETITIVE RISK ANALYSIS. MP25 MS-CPF1: A MODEL-AGNOSTIC INTERPRETABLE COUNTERFACTUAL PERTURBATION FEATURE IMPORTANCE FOR MULTI-STATE MODELS A MP26 FLEXIBLE LOG-HAZARD MODEL FOR ADVERSE EVENTS ANALYSIS MP27 SAMPLE SIZE DETERMINATION BASED ON RESTRICTED MEAN TIME LOST IN THE PRESENCE OF COMPETING RISKS MP28 HANDLING MISSING DISEASE INFORMATION IN DISEASES THAT NEED TWO VISITS TO DIAGNOSE MP39 USING MULTISTATE MODELS TO EXPLORE SOCIODEMOGRAPHIC INFOQUALITIES IN THE ROOF ADVERSE PREGNANCY OUTCOMES MP30 HOW RHEUMATOID ARTHRITIS DISEASE ACTIVITY AFFECTS THE RISK OF CARDIOVASCULAR MULTIMORBIDITY LYMP31 RESTRICTED MEAN TIME LOST MODEL FOR COVARIATES WITH TIME-VARYING EFFECTS MP32 COVID-19 INFECTION IN CHILDREN WITH A CUTTLE TWINDHOLASTIC LEUREMIA IN CHINA: MILD CLINICAL COURSE MP33 DETERMINANTS OF VACCINE INTENTION AGAINST COVID-19: A SERIAL MEDIATION APPROACH MP34 SOCIAL ISOLATION AND MENTAL HEALTH OF OLDER CITIZENS DURING THE COVID-19 PANDEMIC MP35 SOCIAL ISOLATION AND MENTAL HEALTH OF OLDER CITIZENS DURING THE COVID-19 PANDEMIC MP36 SHORT-TERM FORECASTING EVALUATION OF COVID-19 EPIDEMIC WAVES IN THE BASQUE COUNTRY MP37 USEFULNESS OF ECOLOGICAL SOCIO-ECOMOMIC INDICATORS IN SARS-COV-2 INFECTION MODELING: A FRENCH CASE STUDY MP38 OPTIMAL STAGE-WISE ALLOCATION RATIOS IN MULTI-STAGE DESIGNS MP39 A LATERT VARIABLE MODEL FOR BORROWING OF INFORMATION THE SIMILATIVE BETWEEN TWO | Simon Newsome Christian Pipper Giulia Pontali (riWEN XU Iunxian Zhu Urko Aguirre Aziliz Cottin |
| MP20 UNBIASED AND EFFICIENT ESTIMATION OF CAUSAL TREATMENT EFFECTS IN CROSS-OVER TRIALS MP21 COMBINING DATASETS IN A MENDELIAN RANDOMIZATION DESIGN: METABOLOMICS AND PARKINSON'S DISEASE CASE STUDY G MP22 TRIAL EMULATION FOR GROUP POLICIES: IMPACT OF ONLINE CONSULTATION SYSTEM ON EMERGENCY HOSPITAL UTILISATION MP23 ACCOUNTING FOR NON-COMPLIANCE WHEN ESTIMATING TREATMENT EFFECTS OF ORDINAL OUTCOME IN RCT MP24 RISK FACTORS FOR THE SURVIVAL OF COLORECTAL CANCER PATIENTS MODELED THROUGH A COMPETITIVE RISK ANALYSIS. MP25 MS-CPF1: A MODEL-AGNOSTIC INTERPRETABLE COUNTERFACTULAL PERTURBATION FEATURE IMPORTANCE FOR MULTI-STATE MODELS A MP26 FLEXIBLE LOG-HAZARD MODEL FOR ADVERSE EVENTS ANALYSIS MP27 SAMPLE SIZE DETERMINATION BASED ON RESTRICTED MEAN TIME LOST IN THE PRESENCE OF COMPETING RISKS X MP28 HANDDING MISSING DISEASE INFORMATION IN DISEASES THAT NEED TWO VISITS TO DIAGNOSE MP29 USING MULTISTATE MODELS TO EXPLORE SOCIODEMOGRAPHIC INEQUALITIES IN THE RISK OF ADVERSE PREGNANCY OUTCOMES MP30 HOW REUMATOID ARTHRITIS DISEASE ACTIVITY AFFECTS THE RISK OF CARDIOVASCULAR MULTIMORBIDITY LI MP31 RESTRICTED MEAN TIME LOST MODEL FOR COVARIATES WITH TIME-VARYING EFFECTS MP32 COVID-19 INFECTION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN CHINA: MILD CLINICAL COURSE MP33 DETERMINANTS OF VACCINE INTENTION AGAINST COVID-19: A SERIAL MEDIATION APPROACH MP34 SOCIAL ISOLATION AND MENTAL HEALTH OF OLDER CITIZEDS DURING THE COVID-19 PANDEMIC MP35 COVID-19 HEALTH INTERVENTIONS TARGETING MIGRANT POPULATIONS: A SYSTEMATIC REVIEW MP36 SHORT-TERM FORECASTING EVALUATION OF COVID-19: PIDEMIC WAVES IN THE BASQUE COUNTRY MP37 USEFULNESS OF ECOLOGICAL SOCIO-ECONOMIC INDICATORS IN SARS-COV-2 INFECTION MODELING: A FRENCH CASE STUDY MP38 OPTIMAL STAGE-WISE ALLOCATION RATIOS IN MULTI-ARM MULTI-STAGE DESIGNS RM39 A LATENT VARIABLE MODEL FOR BORROWING OF INFORMATION IN A BASKET TRIAL MP40 TOLERANCE INTERVAL-BASED HYPOTHESIS TESTING FOR THE SIMILARITY BETWEEN TWO INDEPPENDENT POPULATIONS C M941 TOLERANCE INTERVAL-BASED HYPOTHES | Giulia Pontali VIWEN XU Iunxian Zhu Jrko Aguirre Aziliz Cottin Elsa COZ |
| MP22 TRIAL EMULATION FOR GROUP POLICIES: IMPACT OF ONLINE CONSULTATION SYSTEM ON EMERGENCY HOSPITAL UTILISATION MP23 ACCOUNTING FOR NON-COMPLIANCE WHEN ESTIMATING TREATMENT EFFECTS OF ORDINAL OUTCOME IN RCT JAMP26 RISK FACTORS FOR THE SURVIVAL OF COLORECTAL CANCER PATHENTS MODELED THAT THE MESS ANALYSIS. MP25 MS-CPFI: A MODEL-AGNOSTIC INTERPRETABLE COUNTERFACTUAL PERTURBATION FEATURE IMPORTANCE FOR MULTI-STATE MODELS A MP26 FLEXIBLE LOG-HAZARD MODEL FOR ADVERSE EVENTS ANALYSIS ELEMP27 SAMPLE SIZE DETERMINATION BASED ON RESTRICTED MEAN TIME LOST IN THE PRESENCE OF COMPETING RISKS MP28 HANDLING MISSING DISEASE INFORMATION IN DISEASES THAT NEED TWO VISITS TO DIAGNOSE MP29 USING MULTISTATE MODELS TO EXPLORE SOCIODEMOGRAPHIC INEQUALITIES IN THE RISK OF ADVERSE PREGNANCY OUTCOMES MP30 HOW RHEUMATION DATHINTIS DISEASE ACTIVITY AFFECTS THE RISK OF CARDIOVASCHAUR MULTIMORBIDITY LEMP31 RESTRICTED MEAN TIME LOST MODEL FOR COVARIATES WITH TIME-VARYING EFFECTS MP31 RESTRICTED MEAN TIME LOST MODEL FOR COVARIATES WITH TIME-VARYING EFFECTS MP32 COVID-19 INFECTION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUREMIA IN CHINA: MILD CURINCIAL COURSE MP33 DETERMINANTS OF VACCINE INTENTION AGAINST COVID-19: A SERIAL MEDIATION APPROACH MP34 SOCIAL ISOLATION AND MENTAL HEALTH OF OLDER CITIZENS DURING THE COVID-19 PANDEMIC AP35 COVID-19 HEALTH INTERVENTIONS TARGETING MIGRANT POPULATIONS: A SYSTEMATIC REVIEW MP36 SHORT-TERM FORECASTING EVALUATION OF COVID-19 PIPIDEMIC WAYES IN THE BASIC COUNTRY MP37 USEFULNESS OF ECOLOGICAL SOCIO-ECONOMIC INDICATORS IN SARS-COV-2 INFECTION MODELING: A FRENCH CASE STUDY MP38 OPTIMAL STAGE-WISE ALLOCATION RATIOS IN MULTI-ARM MULTI-STAGE DESIGNS MP39 A LATENT VARIBBLE MODEL FOR BORROWING OF INFORMATION IN A BASKET TRIAL MP40 TOLERANCE INTERVAL-BASED HYPOTHESIS TESTING FOR THE SIMILARITY BETWEEN TWO INDEPENDENT POPULATIONS C MP41 SAMPLE SIZE RECALCULATION FOR A SKEWED OUTCOME IN TWO-STAGE THREE-ARM SEQUENTIAL NONINFERIORITY CLINICAL TRIAL MP42 USE OF AN ADAPTIVE DESIGN FOR MULTI-ARM MULTI-STA | /IWEN XU Junxian Zhu Jrko Aguirre Aziliz Cottin Elsa COZ |
| MP23 ACCOUNTING FOR NON-COMPLIANCE WHEN ESTIMATING TREATMENT EFFECTS OF ORDINAL OUTCOME IN RCT MP24 RISK FACTORS FOR THE SURVIVAL OF COLORECTAL CANCER PATIENTS MODELED THROUGH A COMPETITIVE RISK ANALYSIS. UNM925 MS-CPFI: A MODEL-AGNOSTIC INTERPRETABLE COUNTERFACTUAL PERTURBATION FEATURE IMPORTANCE FOR MULTI-STATE MODELS A MP26 FLEMBLE LOG-HAZARD MODEL FOR ADVERSE EVENTS ANALYSIS EFFENDE LOG-HAZARD MODEL FOR ADVERSE EVENTS ANALYSIS MP27 SAMPLE SIZE DETERMINATION BASED ON RESTRICTED MEAN TIME LOST IN THE PRESENCE OF COMPETING RISKS X MP28 HANDLING MISSING DISEASE INFORMATION IN DISEASES THAT NEED TWO VISITS TO DIAGNOSE MP29 USING MULTISTATE MODELS TO EXPLORE SOCIODEMOGRAPHIC INEQUALITIES IN THE RISK OF ADVERSE PREGNANCY OUTCOMES MP30 HOW RHEUMATOID ARTHRITIS DISEASE ACTIVITY AFFECTS THE RISK OF CARDIOVASCULAR MULTIMORBIDITY LAMP31 RESTRICTED MEAN TIME LOST MODEL FOR COVARIATES WITH TIME-VARYING EFFECTS MP31 RESTRICTED MEAN TIME LOST MODEL FOR COVARIATES WITH TIME-VARYING EFFECTS MP33 DETERMINANTS OF VACCINE INTENTION AGAINST COVID-19: A SERIAL MEDIATION APPROACH MP34 SOCIAL ISOLATION AND MENTAL HEALTH OF OLDER CHITZENS DURING THE COVID-19 PANDEMIC MP35 SOCIAL ISOLATION AND MENTAL HEALTH OF OLDER CHITZENS DURING THE COVID-19 PANDEMIC MP36 SHORT-TERM FORECASTING EVALUATION OF COVID-19 EPIDEMIC WAVES IN THE BASQUE COUNTRY MP37 USEFULNESS OF ECOLOGICAL SOCIO-ECONOMIC INDICATORS IN SARS-COV-2 INFECTION MODELING: A FRENCH CASE STUDY MP38 A LATERT VARIABLE MODEL FOR BORROWING OF INFORMATION IN A BASKET TRIAL MP49 OPTIMAL STAGE-WISE ALLOCATION RATIOS IN MULTI-STAGE DESIGNS MP40 TOLERANCE INTERVAL-BASED HYPOTHESIS TESTING FOR THE SIMILARITY BETWEEN TWO INDEPENDENT POPULATIONS C MP41 SAMPLE SIZE RECALCULATION FOR A SKEWED OUTCOME IN TWO-STAGE THREE-ARM SEQUENTIAL NONINFERIORITY CLINICAL TRIAL MP42 USE OF AN ADAPTIVE DESIGN IN A RANDOMLY ASSIGNED, OPEN-LABEL, BALANCED MONTORING IN INTENSIVE CARE UNITS MP43 A COMPARISON OF SAMPLE SIZE RE-ESTIMATION METHODS FOR CLUSTER-RANDOMIZED TRIALS MP44 DESIGN OF A | unxian Zhu Jrko Aguirre Aziliz Cottin Elsa COZ |
| MP24 RISK FACTORS FOR THE SURVIVAL OF COLORECTAL CANCER PATIENTS MODELED THROUGH A COMPETITIVE RISK ANALYSIS. MP25 MS-CPFI: A MODEL-AGNOSTIC INTERPRETABLE COUNTERFACTUAL PERTURBATION FEATURE IMPORTANCE FOR MULTI-STATE MODELS A MP26 FLEXIBLE LOG-HAZARD MODEL FOR ADVERSE EVENTS ANALYSIS. E MP27 SAMPLE SIZE DETERMINATION BASED ON RESTRICTED MEAN TIME LOST IN THE PRESENCE OF COMPETING RISKS X MP28 HANDLING MISSING DISEASE INFORMATION IN DISEASES THAT NEED TWO VISITS TO DIAGNOSE MP29 USING MULTISTATE MODELS TO EXPLORE SOCIODEMOGRAPHIC INEQUALITIES IN THE RISK OF ADVERSE PREGNANCY OUTCOMES MP30 HOW RHEUMATOID ARTHRITIS DISEASE ACTIVITY AFFECTS THE RISK OF CARDIOVASCULAR MULTIMORBIDITY L MP31 RESTRICTED MEAN TIME LOST MODEL FOR COVARIATES WITH TIME-VARYING EFFECTS MP32 COVID-19 INFECTION IN CHILDREN WITH ACUTE LYMPHOBILASTIC LEUKEMIA IN CHINA: MILD CLINICAL COURSE MP33 DETERMINANTS OF VACCINE INTENTION AGAINST COVID-19: A SERIAL MEDIATION APPROACH MP34 SOCIAL ISOLATION AND MENTAL HEALTH OF OLDER CITIZENS DURING THE COVID-19 PANDEMIC A PM35 COVID-19 HALTH INTERVENTIONS TARGETING MIGRANT POPULATIONS: A SYSTEMATIC REVIEW MP36 SHORT-TERM FORECASTING EVALUATION OF COVID-19 EPIDEMIC WAVES IN THE BASQUE COUNTRY MP37 USEFULNESS OF ECOLOGICAL SOCIO-ECONOMIC INDICATORS IN SARS-COV-2 INFECTION MODELING: A FRENCH CASE STUDY MP38 OPTIMAL STAGE-WISE ALLOCATION RATIOS IN MULTI-ARM MULTI-STAGE DESIGNS RP39 A LATENT VARIABLE MODEL FOR BORROWING OF INFORMATION IN A BASKET TRIAL MP41 SAMPLE SIZE RECALCULATION FOR A SKEWED OUTCOME IN TWO-STAGE THREE-ARM SEQUENTIAL NONINFERIORITY CLINICAL TRIAL MP42 USE OF AN ADAPTIVE DESIGN IN A RANDOMLY ASSIGNED, OPEN-LABEL, BALANCED INCOMPLETE BLOCK DESIGN STUDY MP43 A COMPARISON OF SAMPLE SIZE RE-ESTIMATION METHODS FOR CLUSTER-RANDOMIZED TRIALS MP44 DESIGN OF A CLUSTER-RANDOMIZED TRIAL: TELEHEALTH-ENABLED PHYSICIAN ADHERECE MONITORING IN INTENSIVE CARE UNITS RP44 DESIGN OF A CLUSTER-RANDOMIZED FINIAL THE DEFIGNED OF OTHE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP49 MOD | Urko Aguirre Aziliz Cottin Elsa COZ |
| MP25 MS-CPFI: A MODEL-AGNOSTIC INTERPRETABLE COUNTERFACTUAL PERTURBATION FEATURE IMPORTANCE FOR MULTI-STATE MODELS A MP26 FLEXIBLE LOG-HAZARD MODEL FOR ADVERSE EVENTS ANALYSIS EN MP27 SAMPLE SIZE DETERMINATION BASED ON RESTRICTED MEAN TIME LOST IN THE PRESENCE OF COMPETING RISKS X MP28 HANDLING MISSING DISEASE INFORMATION IN DISEASES THAT NEED TWO VISITS TO DIAGNOSE MP29 USING MULTISTATE MODELS TO EXPLORE SOCIODEMOGRAPHIC INEQUALITIES IN THE RISK OF ADVERSE PREGNANCY OUTCOMES MP30 HOW RHEUMATOID ARTHRITIS DISEASE ACTIVITY AFFECTS THE RISK OF CARDIOVASCULAR MULTIMORBIDITY USING MULTISTATE MODEL FOR COVARIATES WITH TIME-VARYING EFFECTS MP31 RESTRICTED MEAN TIME LOST MODEL FOR COVARIATES WITH TIME-VARYING EFFECTS MP32 COVID-19 INFECTION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN CHINA: MILD CLINICAL COURSE MP33 DETERMINANTS OF VACCINE INTENTION AGAINST COVID-19: A SERIAL MEDIATION APPROACH MP34 SOCIAL ISOLATION AND MENTAL HEALTH OF OLDER CITIZENS DURING THE COVID-19 PANDEMIC AMP35 COVID-19 HEALTH INTERVENTIONS TARGETING MIGRANT POPULATIONS: A SYSTEMATIC REVIEW MP36 SHORT-TERM FORECASTING EVALUATION OF COVID-19 EPIDEMIC WAVES IN THE BASQUE COUNTRY MP37 USEFULNESS OF ECOLOGICAL SOCIO-ECONOMIC INDICATORS IN SARS-COV-2 INFECTION MODELING: A FRENCH CASE STUDY MP38 OPTIMAL STAGE-WISE ALLOCATION RATIOS IN MULTI-STAGE DESIGNS MP39 A LATENT VARIABLE MODEL FOR BORROWING OF INFORMATION IN A BASKET TRIAL MP40 TOLERANCE INTERVAL-BASED HYPOTHESIS TESTING FOR THE SIMILARITY BETWEEN TWO INDEPENDENT POPULATIONS MP41 SAMPLE SIZE RECALCULATION FOR A SKEWED OUTCOME IN TWO-5TAGE THREE-ARM SEQUENTIAL NONINFERIORITY CLINICAL TRIAL MP42 USE OF AN ADAPTIVE DESIGN IN A RANDOMLY ASSIGNED, OPEN-LABEL, BALANCED INCOMPLETE BLOCK DESIGN STUDY MP43 A COMPARISON OF SAMPLE SIZE RE-ESTIMATION METHODS FOR CLUSTER-RANDOMIZED TRIALS MP44 DESIGN OF A CLUSTER-RANDOMIZED TRIAL: TELEHEALTH-ENABLED PLYSTICIAN ADHERENCE MONITORING IN INTENSIVE CARE UNITS MP45 STATISTICAL VALIDATION FOR A SKEWED OUTCOME TO TWO-5TAGE THREE-ARM SEQU | Aziliz Cottin Elsa COZ |
| MP26 FLEXIBLE LOG-HAZARD MODEL FOR ADVERSE EVENTS ANALYSIS MP27 SAMPLE SIZE DETERMINATION BASED ON RESTRICTED MEAN TIME LOST IN THE PRESENCE OF COMPETING RISKS X MP28 HANDLING MISSING DISEASE INFORMATION IN DISEASES THAT NEED TWO VISITS TO DIAGNOSE MP29 USING MULTISTATE MODELS TO EXPLORE SOCIODEMOGRAPHIC INEQUALITIES IN THE RISK OF ADVERSE PREGNANCY OUTCOMES MP30 HOW RHEUMATOID ARTHRITIS DISEASE ACTIVITY AFFECTS THE RISK OF CARDIOVASCULAR MULTIMORBIDITY LE MP31 RESTRICTED MEAN TIME LOST MODEL FOR COVARIATES WITH TIME-VARYING EFFECTS 22 COVID-19 INFECTION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN CHINA: MILD CLINICAL COURSE MP32 COVID-19 INFECTION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN CHINA: MILD CLINICAL COURSE MP33 DETERMINANTS OF VACCINE INTENTION AGAINST COVID-19: A SERIAL MEDIATION APPROACH MP34 SOCIAL ISOLATION AND MENTAL HEALTH OF OLDER CITIZENS DURING THE COVID-19 PANDEMIC AMP35 COVID-19 HEALTH INTERVENTIONS TARGETING MIGRANT POPULATIONS: A SYSTEMATIC REVIEW SHAP35 SHORT-TERM FORECASTING EVALUATION OF COVID-19 EPIDEMIC WAVES IN THE BASQUE COUNTRY MP36 USEFULNESS OF ECOLOGICAL SOCIO-ECONOMIC INDICATORS IN SARS-COV-2 INFECTION MODELING: A FRENCH CASE STUDY MP37 USEFULNESS OF ECOLOGICAL SOCIO-ECONOMIC INDICATORS IN SARS-COV-2 INFECTION MODELING: A FRENCH CASE STUDY MP38 OPTIMAL STAGE-WISE ALLOCATION RATIOS IN MULTI-ARM MULTI-STAGE DESIGNS MP39 A LATENT VARIABLE MODEL FOR BORROWING OF INFORMATION IN A BASKET TRIAL MP40 TOLERANCE INTERVALA BASED HYPOTHESIS TESTING FOR THE SIMILARITY BETWEEN TWO INDEPENDENT POPULATIONS MP41 SAMPLE SIZE RECALCULATION FOR A SKEWED OUTCOME IN TWO-STAGE THREE-ARM SEQUENTIAL NONINFERIORITY CLINICAL TRIAL MP42 USE OF AN ADAPTIVE DESIGN IN A RANDOMILY ASSIGNED, OPEN-LABEL, BALANCED INCOMPLETE BLOCK DESIGN STUDY MP43 A COMPARISON OF SAMPLE SIZE RE-ESTIMATION METHODS FOR CLUSTER-RANDOMIZED TRIALS HM44 DESIGN OF A CLUSTER-RANDOMIZED TRIAL-TELEHEALTH-ENABLED PHYSICIAN ADHERINCE MONITORING IN INTENSIVE CARE UNITS MP45 STATISTICAL VALIDATION METHODS O | Elsa COZ |
| MP27 SAMPLE SIZE DETERMINATION BASED ON RESTRICTED MEAN TIME LOST IN THE PRESENCE OF COMPETING RISKS MP28 HANDLING MISSING DISEASE INFORMATION IN DISEASES THAT NEED TWO VISITS TO DIAGNOSE MP29 USING MULTISTATE MODELS TO EXPLORE SOCIODEMOGRAPHIC INEQUALITIES IN THE RISK OF ADVERSE PREGNANCY OUTCOMES MP30 HOW RHEUMATOID ARTHRITIS DISEASE ACTIVITY AFFECTS THE RISK OF CARDIOVASCULAR MULTIMORBIDITY LIPATOR MP31 RESTRICTED MEAN TIME LOST MODEL FOR COVARIATES WITH TIME-VARYING EFFECTS MP31 RESTRICTED MEAN TIME LOST MODEL FOR COVARIATES WITH TIME-VARYING EFFECTS MP32 COVID-19 INFECTION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN CHINA: MILLD CLINICAL COURSE MP33 DETERMINANTS OF VACCINE INTENTION AGAINST COVID-19: A SERIAL MEDIATION APPROACH MP34 SOCIAL ISOLATION AND MENTAL HEALTH OF OLDER CITIZENS DURING THE COVID-19 PANDEMIC AP35 COVID-19 HEALTH INTERVENTIONS TARGETING MIGRANT POPULATIONS: A SYSTEMATIC REVIEW MP36 SHORT-TERM FORECASTING EVALUATION OF COVID-19 PEIDEMIC WAVES IN THE BASQUE COUNTRY MP37 USFEULNESS OF ECOLOGICAL SOCIO-ECONOMIC INDICATORS IN SARS-COV2 INFECTION MODELING: A FRENCH CASE STUDY MP38 OPTIMAL STAGE-WISE ALLOCATION RATIOS IN MULTI-ARM MULTI-STAGE DESIGNS MP39 A LATENT VARIABLE MODEL FOR BORROWING OF INFORMATION IN A BASKET TRIAL MP40 TOLERANCE INTERVAL-BASED HYPOTHESIS TESTING FOR THE SIMILARITY BETWEEN TWO INDEPENDENT POPULATIONS MP41 SAMPLE SIZE RECALCULATION FOR A SKEWED OUTCOME IN TWO-STAGE THREE-ARM SEQUENTIAL NONINFERIORITY CLINICAL TRIAL MP42 USE OF AN ADAPTIVE DESIGN IN A RANDOMLY ASSIGNED, OPEN-LABEL, BALANCED INCOMPLETE BLOCK DESIGN STUDY MP43 A COMPARISON OF SAMPLE SIZE RE-ESTIMATION METHODS FOR CLUSTER-RANDOMIZED TRIALS MP44 DESIGN OF A CLUSTER-RANDOMIZED TRIAL-TELEHEALTH-ENABLED PHYSICIAN ADHERENCE MONITORING IN INTENSIVE CARE UNITS MP45 STATISTICAL VALIDATION METHODS OF SOUND RECORDING MEDICAL DEVICE ON RESPIRATORY CLINICAL TRIALS MP46 NON-INFERIORITY TRIALS WITH EVIDENCE OF ASSAY SENSITIVITY USING POPULATION ADJUSTMENT METHOD STATISTICAL VALIDATION METHODS | |
| MP28 HANDLING MISSING DISEASE INFORMATION IN DISEASES THAT NEED TWO VISITS TO DIAGNOSE MP29 USING MULTISTATE MODELS TO EXPLORE SOCIODEMOGRAPHIC INEQUALITIES IN THE RISK OF ADVERSE PREGNANCY OUTCOMES MP30 HOW RHEUMATOID ARTHRITIS DISEASE ACTIVITY AFFECTS THE RISK OF CARDIOVASCULAR MULTIMORBIDITY LIAMP31 RESTRICTED MEAN TIME LOST MODEL FOR COVARIATES WITH TIME-VARRYING EFFECTS MP32 COVID-19 INFECTION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN CHINA: MILD CLINICAL COURSE MP33 DETERMINANTS OF VACCINE INTENTION AGAINST COVID-19: A SERIAL MEDIATION APPROACH MP34 SOCIAL ISOLATION AND MENTAL HEALTH OF OLDER CITIZENS DURING THE COVID-19 PANDEMIC MP35 COVID-19 HEALTH INTERVENTIONS TARGETING MIGRANT POPPULATIONS: A SYSTEMATIC REVIEW MP36 SHORT-TERM FORECASTING EVALUATION OF COVID-19 EPIDEMIC WAVES IN THE BASQUE COUNTRY MP37 USEFULNESS OF ECOLOGICAL SOCIO-ECONOMIC INDICATORS IN SARS-COV-2 INFECTION MODELING: A FRENCH CASE STUDY MP38 OPTIMAL STAGE-WISE ALLOCATION RATIOS IN MULTI-ARM MULTI-STAGE DESIGNS MP39 A LATENT VARIABLE MODEL FOR BORROWING OF INFORMATION IN A BASKET TRIAL MP40 TOLERANCE INTERVAL-BASED HYPOTHESIS TESTING FOR THE SIMILARITY BETWEEN TWO INDEPENDENT POPULATIONS MP41 SAMPLE SIZE RECALCULATION FOR A SKEWED OUTCOME IN TWO-STAGE THREE-ARM SEQUENTIAL NONINFERIORITY CLINICAL TRIAL MP42 USE OF AN ADAPTIVE DESIGN IN A RANDOMLY ASSIGNED, OPEN-LABEL, BALANCED INCOMPLETE BLOCK DESIGN STUDY NAMP43 A COMPARISON OF SAMPLE SIZE RE-ESTIMATION METHODS FOR CLUSTER-RANDOMIZED TRIALS MP44 DESIGN OF A CLUSTER-RANDOMIZED TRIAL: TELEHERALTH-ENABLED PHYSICIAN ADHERENCE MONITORING IN INTENSIVE CARE UNITS MP45 STATISTICAL VALIDATION METHODS OF SOUND RECORDING MEDICAL DEVICE ON RESPIRATORY CLINICAL TRIALS MP46 NON-INFERIORITY TRIALS WITH EVIDENCE OF ASSAY SENSITIVITY USING POPULATION ADJUSTMENT METHOD SENSON OF THE STRUCTURE OF THE STRUCTURE OF THE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP49 WHEN COVID-19 SPECIFIC VACCINES BECAME AN INTERCURRENT EVENT MP49 MODELLING THE RATE OF CHANGE OF GFR I | HOLIS OCHS |
| MP30 HOW RHEUMATOID ARTHRITIS DISEASE ACTIVITY AFFECTS THE RISK OF CARDIOVASCULAR MULTIMORBIDITY MP31 RESTRICTED MEAN TIME LOST MODEL FOR COVARIATES WITH TIME-VARYING EFFECTS MP32 COVID-19 INFECTION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN CHINA: MILD CLINICAL COURSE MP33 DETERMINANTS OF VACCINE INTENTION AGAINST COVID-19: A SERIAL MEDIATION APPROACH MP34 SOCIAL ISOLATION AND MENTAL HEALTH OF OLDER CITIZENS DURING THE COVID-19 PANDEMIC AMP35 COVID-19 HEALTH INTERVENTIONS TARGETING MIGRANT POPULATIONS: A SYSTEMATIC REVIEW MP36 SHORT-TERM FORECASTING EVALUATION OF COVID-19 EPIDEMIC WAVES IN THE BASQUE COUNTRY MP37 USEFULNESS OF ECOLOGICAL SOCIO-ECONOMIC INDICATORS IN SARS-COV-2 INFECTION MODELING: A FRENCH CASE STUDY MP38 OPTIMAL STAGE-WISE ALLOCATION RATIOS IN MULTI-ARM MULTI-ATM MULTI-STAGE DESIGNS MP39 A LATENT VARIABLE MODEL FOR BORROWING OF INFORMATION IN A BASKET TRIAL SSAMPLE SIZE RECALCULATION FOR A SKEWED OUTCOME IN TWO-STAGE THREE-ARM SEQUENTIAL NONINFERIORITY CLINICAL TRIAL MP40 TOLERANCE INTERVAL-BASED HYPOTHESIS TESTING FOR THE SIMILARITY BETWEEN TWO INDEPENDENT POPULATIONS MP41 SAMPLE SIZE RECALCULATION FOR A SKEWED OUTCOME IN TWO-STAGE THREE-ARM SEQUENTIAL NONINFERIORITY CLINICAL TRIAL MP42 USE OF AN ADAPTIVE DESIGN IN A RANDOMLY ASSIGNED, OPEN-LABEL, BALANCED INCOMPLETE BLOCK DESIGN STUDY MP43 A COMPARISON OF SAMPLE SIZE RE-ESTIMATION METHODS FOR CLUSTER-RANDOMIZED TRIALS MP44 DESIGN OF A CLUSTER-RANDOMIZED TRIAL:TELEHEALTH-ENABLED PHYSICIAN ADHERENCE MONITORING IN INTENSIVE CARE UNITS RM45 STATISTICAL VALIDATION METHODS OF SOUND RECORDING MEDICAL DEVICE ON RESPIRATORY CLINICAL TRIALS MP46 NON-INFERIORITY TRIALS WITH EVIDENCE OF ASSAY SENSITIVITY USING POPULATION ADJUSTMENT METHOD SSAMPLES STATISTICAL VALIDATION METHODS OF SOUND RECORDING MEDICAL DEVICE ON RESPIRATORY CLINICAL TRIALS MP47 WHEN COVID-19 SPECIFIC VACCINES BECAME AN INTERCURRENT EVENT MP48 EXPERIENCES WITH A BAYESIAN ADAPTIVE DESIGN FOR THE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP49 MODELLIN | Гћао Le |
| MP31 RESTRICTED MEAN TIME LOST MODEL FOR COVARIATES WITH TIME-VARYING EFFECTS MP32 COVID-19 INFECTION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN CHINA: MILD CLINICAL COURSE MP33 DETERMINANTS OF VACCINE INTENTION AGAINST COVID-19: A SERIAL MEDIATION APPROACH MP34 SOCIAL ISOLATION AND MENTAL HEALTH OF OLDER CITIZENS DURING THE COVID-19 PANDEMIC A MP35 COVID-19 HEALTH INTERVENTIONS TARGETING MIGRANT POPULATIONS: A SYSTEMATIC REVIEW MP36 SHORT-TERM FORECASTING EVALUATION OF COVID-19 EPIDEMIC WAVES IN THE BASQUE COUNTRY MP37 USEFULNESS OF ECOLOGICAL SOCIO-ECONOMIC INDICATORS IN SARS-COV-2 INFECTION MODELING: A FRENCH CASE STUDY MP38 OPTIMAL STAGE-WISE ALLOCATION RATIOS IN MULTI-ARM MULTI-STAGE DESIGNS MP39 A LATENT VARIABLE MODEL FOR BORROWING OF INFORMATION IN A BASKET TRIAL MP40 TOLERANCE INTERVAL-BASED HYPOTHESIS TESTING FOR THE SIMILARITY BETWEEN TWO INDEPENDENT POPULATIONS MP41 SAMPLE SIZE RECALCULATION FOR A SKEWED OUTCOME IN TWO-STAGE THREE-ARM SEQUENTIAL NONINFERIORITY CLINICAL TRIAL MP42 USE OF AN ADAPTIVE DESIGN IN A RANDOMLY ASSIGNED, OPEN-LABEL, BALANCED INCOMPLETE BLOCK DESIGN STUDY MP43 A COMPARISON OF SAMPLE SIZE RE-ESTIMATION METHODS FOR CLUSTER-RANDOMIZED TRIALS MP44 DESIGN OF A CLUSTER-RANDOMIZED TRIAL:TELEHEALTH-ENABLED PHYSICIAN ADHERENCE MONITORING IN INTENSIVE CARE UNITS MP45 STATISTICAL VALIDATION METHODS OF SOUND RECORDING MEDICAL DEVICE ON RESPIRATORY CLINICAL TRIALS MP46 NON-INFERIORITY TRIALS WITH EVIDENCE OF ASSAY SENSITIVITY USING POPULATION ADJUSTMENT METHOD MP47 WHEN COVID-19 SPECIFIC VACCINES BECAME AN INTERCURRENT EVENT MP48 EXPERIENCES WITH A BAYESIAN ADAPTIVE DESIGN FOR THE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP49 MODELLING THE RATE OF CHANGE OF GFR IN THE PRESENCE OF COMPETING RISKS | Megan McGovern |
| MP32 COVID-19 INFECTION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN CHINA: MILD CLINICAL COURSE MP33 DETERMINANTS OF VACCINE INTENTION AGAINST COVID-19: A SERIAL MEDIATION APPROACH MP34 SOCIAL ISOLATION AND MENTAL HEALTH OF OLDER CITIZENS DURING THE COVID-19 PANDEMIC MP35 COVID-19 HEALTH INTERVENTIONS TARGETING MIGRANT POPULATIONS: A SYSTEMATIC REVIEW MP36 SHORT-TERM FORECASTING EVALUATION OF COVID-19 EPIDEMIC WAVES IN THE BASQUE COUNTRY MP37 USEFULNESS OF ECOLOGICAL SOCIO-ECONOMIC INDICATORS IN SARS-COV-2 INFECTION MODELING: A FRENCH CASE STUDY MP38 OPTIMAL STAGE-WISE ALLOCATION RATIOS IN MULTI-ARM MULTI-STAGE DESIGNS MP39 A LATENT VARIABLE MODEL FOR BORROWING OF INFORMATION IN A BASKET TRIAL MP40 TOLERANCE INTERVAL-BASED HYPOTHESIS TESTING FOR THE SIMILARITY BETWEEN TWO INDEPENDENT POPULATIONS MP41 SAMPLE SIZE RECALCULATION FOR A SKEWED OUTCOME IN TWO-STAGE THREE-ARM SEQUENTIAL NONINFERIORITY CLINICAL TRIAL MP42 USE OF AN ADAPTIVE DESIGN IN A RANDOMLY ASSIGNED, OPEN-LABEL, BALANCED INCOMPLETE BLOCK DESIGN STUDY MP43 A COMPARISON OF SAMPLE SIZE RE-ESTIMATION METHODS FOR CLUSTER-RANDOMIZED TRIALS MP44 DESIGN OF A CLUSTER-RANDOMIZED TRIAL:TELEHEALTH-ENABLED PHYSICIAN ADHERENCE MONITORING IN INTENSIVE CARE UNITS MP45 STATISTICAL VALIDATION METHODS OF SOUND RECORDING MEDICAL DEVICE ON RESPIRATORY CLINICAL TRIALS MP46 NON-INFERIORITY TRIALS WITH EVIDENCE OF ASSAY SENSITIVITY USING POPULATION ADJUSTMENT METHOD SENSOR OF A WITH A BAYESIAN ADAPTIVE DESIGN FOR THE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP49 WHEN COVID-19 SPECIFIC VACCINES BECAME AN INTERCURRENT EVENT MP48 EXPERIENCES WITH A BAYESIAN ADAPTIVE DESIGN FOR THE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP49 MODELLING THE RATE OF CHANGE OF GFR IN THE PRESENCE OF COMPETING RISKS | Lauren Rengger |
| MP33 DETERMINANTS OF VACCINE INTENTION AGAINST COVID-19: A SERIAL MEDIATION APPROACH MP34 SOCIAL ISOLATION AND MENTAL HEALTH OF OLDER CITIZENS DURING THE COVID-19 PANDEMIC MP35 COVID-19 HEALTH INTERVENTIONS TARGETING MIGRANT POPULATIONS: A SYSTEMATIC REVIEW MP36 SHORT-TERM FORECASTING EVALUATION OF COVID-19 EPIDEMIC WAVES IN THE BASQUE COUNTRY MP37 USEFULNESS OF ECOLOGICAL SOCIO-ECONOMIC INDICATORS IN SARS-COV-2 INFECTION MODELING: A FRENCH CASE STUDY MP38 OPTIMAL STAGE-WISE ALLOCATION RATIOS IN MULTI-ARM MULTI-STAGE DESIGNS MP39 A LATENT VARIABLE MODEL FOR BORROWING OF INFORMATION IN A BASKET TRIAL MP40 TOLERANCE INTERVAL-BASED HYPOTHESIS TESTING FOR THE SIMILARITY BETWEEN TWO INDEPENDENT POPULATIONS MP41 SAMPLE SIZE RECALCULATION FOR A SKEWED OUTCOME IN TWO-STAGE THREE-ARM SEQUENTIAL NONINFERIORITY CLINICAL TRIAL MP42 USE OF AN ADAPTIVE DESIGN IN A RANDOMLY ASSIGNED, OPEN-LABEL, BALANCED INCOMPLETE BLOCK DESIGN STUDY MP43 A COMPARISON OF SAMPLE SIZE RE-ESTIMATION METHODS FOR CLUSTER-RANDOMIZED TRIALS MP44 DESIGN OF A CLUSTER-RANDOMIZED TRIAL-TELEHEALTH-ENABLED PHYSICIAN ADHERENCE MONITORING IN INTENSIVE CARE UNITS MP45 STATISTICAL VALIDATION METHODS OF SOUND RECORDING MEDICAL DEVICE ON RESPIRATORY CLINICAL TRIALS MP46 NON-INFERIORITY TRIALS WITH EVIDENCE OF ASSAY SENSITIVITY USING POPULATION ADJUSTMENT METHOD MP47 WHEN COVID-19 SPECIFIC VACCINES BECAME AN INTERCURRENT EVENT MP48 EXPERIENCES WITH A BAYESIAN ADAPTIVE DESIGN FOR THE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP49 MODELLING THE RATE OF CHANGE OF GFR IN THE PRESENCE OF COMPETING RISKS | zhiyin yu |
| MP34 SOCIAL ISOLATION AND MENTAL HEALTH OF OLDER CITIZENS DURING THE COVID-19 PANDEMIC MP35 COVID-19 HEALTH INTERVENTIONS TARGETING MIGRANT POPULATIONS: A SYSTEMATIC REVIEW MP36 SHORT-TERM FORECASTING EVALUATION OF COVID-19 EPIDEMIC WAVES IN THE BASQUE COUNTRY MP37 USEFULNESS OF ECOLOGICAL SOCIO-ECONOMIC INDICATORS IN SARS-COV-2 INFECTION MODELING: A FRENCH CASE STUDY MP38 OPTIMAL STAGE-WISE ALLOCATION RATIOS IN MULTI-ARM MULTI-STAGE DESIGNS MP39 A LATENT VARIABLE MODEL FOR BORROWING OF INFORMATION IN A BASKET TRIAL MP40 TOLERANCE INTERVAL-BASED HYPOTHESIS TESTING FOR THE SIMILARITY BETWEEN TWO INDEPENDENT POPULATIONS MP41 SAMPLE SIZE RECALCULATION FOR A SKEWED OUTCOME IN TWO-STAGE THREE-ARM SEQUENTIAL NONINFERIORITY CLINICAL TRIAL MP42 USE OF AN ADAPTIVE DESIGN IN A RANDOMLY ASSIGNED, OPEN-LABEL, BALANCED INCOMPLETE BLOCK DESIGN STUDY MP43 A COMPARISON OF SAMPLE SIZE RE-ESTIMATION METHODS FOR CLUSTER-RANDOMIZED TRIALS MP44 DESIGN OF A CLUSTER-RANDOMIZED TRIAL-TELEHEALTH-ENABLED PHYSICIAN ADHERENCE MONITORING IN INTENSIVE CARE UNITS MP45 STATISTICAL VALIDATION METHODS OF SOUND RECORDING MEDICAL DEVICE ON RESPIRATORY CLINICAL TRIALS MP46 NON-INFERIORITY TRIALS WITH EVIDENCE OF ASSAY SENSITIVITY USING POPULATION ADJUSTMENT METHOD SENDENCE OF CHANGE OF CHANGE OF GER IN THE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP48 EXPERIENCES WITH A BAYESIAN ADAPTIVE DESIGN FOR THE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP49 MODELLING THE RATE OF CHANGE OF GER IN THE PRESENCE OF COMPETING RISKS | iaoyang cai |
| MP35 COVID-19 HEALTH INTERVENTIONS TARGETING MIGRANT POPULATIONS: A SYSTEMATIC REVIEW MP36 SHORT-TERM FORECASTING EVALUATION OF COVID-19 EPIDEMIC WAVES IN THE BASQUE COUNTRY MP37 USEFULNESS OF ECOLOGICAL SOCIO-ECONOMIC INDICATORS IN SARS-COV-2 INFECTION MODELING: A FRENCH CASE STUDY MP38 OPTIMAL STAGE-WISE ALLOCATION RATIOS IN MULTI-ARM MULTI-STAGE DESIGNS MP39 OF LATENT VARIABLE MODEL FOR BORROWING OF INFORMATION IN A BASKET TRIAL MP40 TOLERANCE INTERVAL-BASED HYPOTHESIS TESTING FOR THE SIMILARITY BETWEEN TWO INDEPENDENT POPULATIONS MP41 SAMPLE SIZE RECALCULATION FOR A SKEWED OUTCOME IN TWO-STAGE THREE-ARM SEQUENTIAL NONINFERIORITY CLINICAL TRIAL MP42 USE OF AN ADAPTIVE DESIGN IN A RANDOMLY ASSIGNED, OPEN-LABEL, BALANCED INCOMPLETE BLOCK DESIGN STUDY MP43 A COMPARISON OF SAMPLE SIZE RE-ESTIMATION METHODS FOR CLUSTER-RANDOMIZED TRIALS MP44 DESIGN OF A CLUSTER-RANDOMIZED TRIAL-TELEHEALTH-ENABLED PHYSICIAN ADHERENCE MONITORING IN INTENSIVE CARE UNITS MP45 STATISTICAL VALIDATION METHODS OF SOUND RECORDING MEDICAL DEVICE ON RESPIRATORY CLINICAL TRIALS MP46 NON-INFERIORITY TRIALS WITH EVIDENCE OF ASSAY SENSITIVITY USING POPULATION ADJUSTMENT METHOD MP47 WHEN COVID-19 SPECIFIC VACCINES BECAME AN INTERCURRENT EVENT MP48 EXPERIENCES WITH A BAYESIAN ADAPTIVE DESIGN FOR THE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP49 MODELLING THE RATE OF CHANGE OF GFR IN THE PRESENCE OF COMPETING RISKS | nadia dardenne Anikó Lovik |
| MP36 SHORT-TERM FORECASTING EVALUATION OF COVID-19 EPIDEMIC WAVES IN THE BASQUE COUNTRY MP37 USEFULNESS OF ECOLOGICAL SOCIO-ECONOMIC INDICATORS IN SARS-COV-2 INFECTION MODELING: A FRENCH CASE STUDY MP38 OPTIMAL STAGE-WISE ALLOCATION RATIOS IN MULTI-ARM MULTI-STAGE DESIGNS MP39 A LATENT VARIABLE MODEL FOR BORROWING OF INFORMATION IN A BASKET TRIAL MP40 TOLERANCE INTERVAL-BASED HYPOTHESIS TESTING FOR THE SIMILARITY BETWEEN TWO INDEPENDENT POPULATIONS MP41 SAMPLE SIZE RECALCULATION FOR A SKEWED OUTCOME IN TWO-STAGE THREE-ARM SEQUENTIAL NONINFERIORITY CLINICAL TRIAL MP42 USE OF AN ADAPTIVE DESIGN IN A RANDOMLY ASSIGNED, OPEN-LABEL, BALANCED INCOMPLETE BLOCK DESIGN STUDY MP43 A COMPARISON OF SAMPLE SIZE RE-ESTIMATION METHODS FOR CLUSTER-RANDOMIZED TRIALS MP44 DESIGN OF A CLUSTER-RANDOMIZED TRIAL-TELEHEALTH-ENABLED PHYSICIAN ADHERENCE MONITORING IN INTENSIVE CARE UNITS MP45 STATISTICAL VALIDATION METHODS OF SOUND RECORDING MEDICAL DEVICE ON RESPIRATORY CLINICAL TRIALS MP46 NON-INFERIORITY TRIALS WITH EVIDENCE OF ASSAY SENSITIVITY USING POPULATION ADJUSTMENT METHOD MP47 WHEN COVID-19 SPECIFIC VACCINES BECAME AN INTERCURRENT EVENT MP48 EXPERIENCES WITH A BAYESIAN ADAPTIVE DESIGN FOR THE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP49 MODELLING THE RATE OF CHANGE OF GFR IN THE PRESENCE OF COMPETING RISKS | Stefania Mondello |
| MP38 OPTIMAL STAGE-WISE ALLOCATION RATIOS IN MULTI-ARM MULTI-STAGE DESIGNS MP39 A LATENT VARIABLE MODEL FOR BORROWING OF INFORMATION IN A BASKET TRIAL MP40 TOLERANCE INTERVAL-BASED HYPOTHESIS TESTING FOR THE SIMILARITY BETWEEN TWO INDEPENDENT POPULATIONS MP41 SAMPLE SIZE RECALCULATION FOR A SKEWED OUTCOME IN TWO-STAGE THREE-ARM SEQUENTIAL NONINFERIORITY CLINICAL TRIAL MP42 USE OF AN ADAPTIVE DESIGN IN A RANDOMLY ASSIGNED, OPEN-LABEL, BALANCED INCOMPLETE BLOCK DESIGN STUDY MP43 A COMPARISON OF SAMPLE SIZE RE-ESTIMATION METHODS FOR CLUSTER-RANDOMIZED TRIALS MP44 DESIGN OF A CLUSTER-RANDOMIZED TRIAL:TELEHEALTH-ENABLED PHYSICIAN ADHERNCE MONITORING IN INTENSIVE CARE UNITS RMP45 STATISTICAL VALIDATION METHODS OF SOUND RECORDING MEDICAL DEVICE ON RESPIRATORY CLINICAL TRIALS MP46 NON-INFERIORITY TRIALS WITH EVIDENCE OF ASSAY SENSITIVITY USING POPULATION ADJUSTMENT METHOD MP47 WHEN COVID-19 SPECIFIC VACCINES BECAME AN INTERCURRENT EVENT MP48 EXPERIENCES WITH A BAYESIAN ADAPTIVE DESIGN FOR THE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP49 MODELLING THE RATE OF CHANGE OF GFR IN THE PRESENCE OF COMPETING RISKS | lose M Quintana |
| MP39 A LATENT VARIABLE MODEL FOR BORROWING OF INFORMATION IN A BASKET TRIAL MP40 TOLERANCE INTERVAL-BASED HYPOTHESIS TESTING FOR THE SIMILARITY BETWEEN TWO INDEPENDENT POPULATIONS MP41 SAMPLE SIZE RECALCULATION FOR A SKEWED OUTCOME IN TWO-STAGE THREE-ARM SEQUENTIAL NONINFERIORITY CLINICAL TRIAL MP42 USE OF AN ADAPTIVE DESIGN IN A RANDOMLY ASSIGNED, OPEN-LABEL, BALANCED INCOMPLETE BLOCK DESIGN STUDY MP43 A COMPARISON OF SAMPLE SIZE RE-ESTIMATION METHODS FOR CLUSTER-RANDOMIZED TRIALS MP44 DESIGN OF A CLUSTER-RANDOMIZED TRIAL:TELEHEALTH-ENABLED PHYSICIAN ADHERENCE MONITORING IN INTENSIVE CARE UNITS R MP45 STATISTICAL VALIDATION METHODS OF SOUND RECORDING MEDICAL DEVICE ON RESPIRATORY CLINICAL TRIALS MP46 NON-INFERIORITY TRIALS WITH EVIDENCE OF ASSAY SENSITIVITY USING POPULATION ADJUSTMENT METHOD MP47 WHEN COVID-19 SPECIFIC VACCINES BECAME AN INTERCURRENT EVENT MP48 EXPERIENCES WITH A BAYESIAN ADAPTIVE DESIGN FOR THE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP49 MODELLING THE RATE OF CHANGE OF GFR IN THE PRESENCE OF COMPETING RISKS | Nicolas ROMAIN-SCELLE |
| MP40 TOLERANCE INTERVAL-BASED HYPOTHESIS TESTING FOR THE SIMILARITY BETWEEN TWO INDEPENDENT POPULATIONS MP41 SAMPLE SIZE RECALCULATION FOR A SKEWED OUTCOME IN TWO-STAGE THREE-ARM SEQUENTIAL NONINFERIORITY CLINICAL TRIAL MP42 USE OF AN ADAPTIVE DESIGN IN A RANDOMLY ASSIGNED, OPEN-LABEL, BALANCED INCOMPLETE BLOCK DESIGN STUDY MP43 A COMPARISON OF SAMPLE SIZE RE-ESTIMATION METHODS FOR CLUSTER-RANDOMIZED TRIALS MP44 DESIGN OF A CLUSTER-RANDOMIZED TRIAL:TELEHEALTH-ENABLED PHYSICIAN ADHERENCE MONITORING IN INTENSIVE CARE UNITS RMP45 STATISTICAL VALIDATION METHODS OF SOUND RECORDING MEDICAL DEVICE ON RESPIRATORY CLINICAL TRIALS AMP46 NON-INFERIORITY TRIALS WITH EVIDENCE OF ASSAY SENSITIVITY USING POPULATION ADJUSTMENT METHOD MP47 WHEN COVID-19 SPECIFIC VACCINES BECAME AN INTERCURRENT EVENT MP48 EXPERIENCES WITH A BAYESIAN ADAPTIVE DESIGN FOR THE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP49 MODELLING THE RATE OF CHANGE OF GFR IN THE PRESENCE OF COMPETING RISKS | Ruqayya Azher |
| MP41 SAMPLE SIZE RECALCULATION FOR A SKEWED OUTCOME IN TWO-STAGE THREE-ARM SEQUENTIAL NONINFERIORITY CLINICAL TRIAL MP42 USE OF AN ADAPTIVE DESIGN IN A RANDOMLY ASSIGNED, OPEN-LABEL, BALANCED INCOMPLETE BLOCK DESIGN STUDY MP43 A COMPARISON OF SAMPLE SIZE RE-ESTIMATION METHODS FOR CLUSTER-RANDOMIZED TRIALS MP44 DESIGN OF A CLUSTER-RANDOMIZED TRIAL-TELEHEALTH-ENABLED PHYSICIAN ADHERENCE MONITORING IN INTENSIVE CARE UNITS RMP45 STATISTICAL VALIDATION METHODS OF SOUND RECORDING MEDICAL DEVICE ON RESPIRATORY CLINICAL TRIALS AMP46 NON-INFERIORITY TRIALS WITH EVIDENCE OF ASSAY SENSITIVITY USING POPULATION ADJUSTMENT METHOD SYMPHON OVID-19 SPECIFIC VACCINES BECAME AN INTERCURRENT EVENT MP48 EXPERIENCES WITH A BAYESIAN ADAPTIVE DESIGN FOR THE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP49 MODELLING THE RATE OF CHANGE OF GFR IN THE PRESENCE OF COMPETING RISKS | Svetlana Cherlin |
| MP42 USE OF AN ADAPTIVE DESIGN IN A RANDOMLY ASSIGNED, OPEN-LABEL, BALANCED INCOMPLETE BLOCK DESIGN STUDY MP43 A COMPARISON OF SAMPLE SIZE RE-ESTIMATION METHODS FOR CLUSTER-RANDOMIZED TRIALS MP44 DESIGN OF A CLUSTER-RANDOMIZED TRIAL:TELEHEALTH-ENABLED PHYSICIAN ADHERENCE MONITORING IN INTENSIVE CARE UNITS MP45 STATISTICAL VALIDATION METHODS OF SOUND RECORDING MEDICAL DEVICE ON RESPIRATORY CLINICAL TRIALS AMP46 NON-INFERIORITY TRIALS WITH EVIDENCE OF ASSAY SENSITIVITY USING POPULATION ADJUSTMENT METHOD MP47 WHEN COVID-19 SPECIFIC VACCINES BECAME AN INTERCURRENT EVENT MP48 EXPERIENCES WITH A BAYESIAN ADAPTIVE DESIGN FOR THE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP49 MODELLING THE RATE OF CHANGE OF GFR IN THE PRESENCE OF COMPETING RISKS | Chieh Chiang Maria Vittoria Chiaruttini |
| MP43 A COMPARISON OF SAMPLE SIZE RE-ESTIMATION METHODS FOR CLUSTER-RANDOMIZED TRIALS MP44 DESIGN OF A CLUSTER-RANDOMIZED TRIAL:TELEHEALTH-ENABLED PHYSICIAN ADHERENCE MONITORING IN INTENSIVE CARE UNITS RM45 STATISTICAL VALIDATION METHODS OF SOUND RECORDING MEDICAL DEVICE ON RESPIRATORY CLINICAL TRIALS AMP46 NON-INFERIORITY TRIALS WITH EVIDENCE OF ASSAY SENSITIVITY USING POPULATION ADJUSTMENT METHOD MP47 WHEN COVID-19 SPECIFIC VACCINES BECAME AN INTERCURRENT EVENT MP48 EXPERIENCES WITH A BAYESIAN ADAPTIVE DESIGN FOR THE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP49 MODELLING THE RATE OF CHANGE OF GFR IN THE PRESENCE OF COMPETING RISKS | Noura Darwish |
| MP44 DESIGN OF A CLUSTER-RANDOMIZED TRIAL:TELEHEALTH-ENABLED PHYSICIAN ADHERENCE MONITORING IN INTENSIVE CARE UNITS MP45 STATISTICAL VALIDATION METHODS OF SOUND RECORDING MEDICAL DEVICE ON RESPIRATORY CLINICAL TRIALS MP46 NON-INFERIORITY TRIALS WITH EVIDENCE OF ASSAY SENSITIVITY USING POPULATION ADJUSTMENT METHOD MP47 WHEN COVID-19 SPECIFIC VACCINES BECAME AN INTERCURRENT EVENT MP48 EXPERIENCES WITH A BAYESIAN ADAPTIVE DESIGN FOR THE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP49 MODELLING THE RATE OF CHANGE OF GFR IN THE PRESENCE OF COMPETING RISKS | Heather Gunn |
| MP46 NON-INFERIORITY TRIALS WITH EVIDENCE OF ASSAY SENSITIVITY USING POPULATION ADJUSTMENT METHOD MP47 WHEN COVID-19 SPECIFIC VACCINES BECAME AN INTERCURRENT EVENT MP48 EXPERIENCES WITH A BAYESIAN ADAPTIVE DESIGN FOR THE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP49 MODELLING THE RATE OF CHANGE OF GFR IN THE PRESENCE OF COMPETING RISKS JC JC JC JC JC JC JC JC JC J | Richard Holubkov |
| MP47 WHEN COVID-19 SPECIFIC VACCINES BECAME AN INTERCURRENT EVENT MP48 EXPERIENCES WITH A BAYESIAN ADAPTIVE DESIGN FOR THE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP49 MODELLING THE RATE OF CHANGE OF GFR IN THE PRESENCE OF COMPETING RISKS JC JC JC JC JC JC JC JC JC J | Athina Kranidi |
| MP48 EXPERIENCES WITH A BAYESIAN ADAPTIVE DESIGN FOR THE EVALUATION OF A BIOMARKER-BASED TREATMENT ALGORITHM MP49 MODELLING THE RATE OF CHANGE OF GFR IN THE PRESENCE OF COMPETING RISKS JC JC JC JC JC JC JC JC JC J | Satomi Okamura |
| MP49 MODELLING THE RATE OF CHANGE OF GFR IN THE PRESENCE OF COMPETING RISKS | Francesca Orsini |
| | lan Wiemer Iohn Belcher |
| | Ricarda Graf |
| | Eleonore Herquelot |
| | Sofia Kaisaridi |
| | (ylie Lange |
| | Annalisa Orenti |
| | Faesung Park |
| ESTIMATION OF A MORE BY EXCEPTION OF A MORE BY MAKES | Jules Pereira Macedo Diana Trutschel |
| | SARA ALBASINI |
| | ucas Anzelin |
| | asai Barreñada |
| | Benoit Courbon |
| | Eleonora Di Carluccio |
| | Sarah Friedrich |
| | ankam tana |
| | Gaebom Jeon Marzieh Mahmudimanesh |
| | Marzieh Mahmudimanesh |
| | |
| | Marzieh Mahmudimanesh Autumn O'Donnell |
| MP70 CLASSIFICATION OF METABOLIC SYNDROME USING ARTERIAL PULSE WAVE VIA MACHINE LEARNING APPROACHES | Marzieh Mahmudimanesh Autumn O'Donnell osline Adhiambo Otieno |

Τ



MP131

MP133

MP134

MP135





Monday 28th August 2023 TITLE **PRESENTER** ID Abstract MP71 ADVANCED STATISTICAL METHODS OF HANDLING ORDINAL MISSING DATA Omololu Aluko MP72 USING EARLY OR BASELINE DATA IN A TRIAL WITH MISSINGNESS IN A CONTINUOUS PRIMARY ENDPOINT oydeep Basi EVALUATING BIAS WHEN ESTIMATING CAUSAL MEDIATION ESTIMANDS WITH NON-ADHERENCE AND MISSING DATA Anca Chis Ster MP74 SIMULATION STUDY OF FOUR METHODS FOR SENSITIVITY ANALYSIS OF THE MAR ASSUMPTION WITH AN APPLICATION TO RCTS Daisy Gaunt MP75 EXPERT ELICITATION METHODS FOR THE EVALUATION OF MISSING DATA ASSUMPTIONS: A SCOPING REVIEW Sophie Greenwood MP76 CORRECTING FOR BIAS DUE TO MISSING DATA IN LONGITUDINAL STUDIES ON QUALITY OF CANCER PATIENTS Nina Haug MP77 ACCOUNTING FOR DATA MISSING NOT AT RANDOM: COMPARISON OF BAYESIAN AND MONTE CARLO PROBABILISTIC BIAS ANALYSES MP78 METHODS OF DEALING WITH ATTRITION BIAS DUE TO NON-RANDOM DROPOUT IN MODELS WITH BINARY OUTCOME Markéta Janošova MP79 Shahab Jolani IMPUTATION OF CROSS-CLASSIFIED MULTILEVEL MODELS MP80 COMBINING MULTIPLE IMPUTATION AND INVERSE PROBABILITY WEIGHTING TO HANDLE MISSING DATA IN LONGITUDINAL STUDIES Melissa Middletor MP81 INSTABILITY OF CLINICAL PREDICTION MODELS CAUSED BY DICHOTOMISATION OF A CONTINUOUS OUTCOME Lucinda Archer MP82 REAL-TIME DETECTION OF HIV OUTBREAKS AMONG PEOPLE WHO INJECT DRUGS AND MODELLING OF SUBSEQUENT EPIDEMIC STATES VASILIKI BARALOU MP83 STUDIES DEVELOPING PREDICTION MODELS ARE NOT CONSIDERING SAMPLE SIZE REQUIREMENTS: A SYSTEMATIC REVIEW Paula Dhiman A COMPARISON OF HYPERPARAMETER TUNING PROCEDURES FOR CLINICAL PREDICTION MODELS: A SIMULATION STUDY MP84 Zoë Dunias MP85 CLINICAL UTILITY CURVE: A NEW PROPOSAL TO ANALYZE THE UTILITY OF PREDICTIVE MODELS María Escorihuela MP86 PREDICTING CENTRAL LINE-ASSOCIATED BLOODSTREAM INFECTIONS IN HOSPITALIZED PATIENTS: A SYSTEMATIC REVIEW Shan Gao Frissiano Honwana MP87 EXTENDED JOINT MODELS FOR LONGITUDINAL VIRAL LOAD AND VIROLOGIC FAILURE IN HIV AT WESTERN CAPE (SOUTH AFRICA) MP88 CLINICAL PREDICTION MODELS FOR TRANSITION TO PSYCHOSIS IN INDIVIDUALS MEETING AT RISK MENTAL STATE CRITERIA Alexandra Hunt MP89 RISK PREDICTION MODELS FOR INDIVIDUAL DIAGNOSIS: A PROSTATE CANCER CASE STUDY Amir Jalali MP90 REAL TIME PREDICTION OF INFECTIOUS DISEASE OUTBREAKS BASED ON GOOGLE TREND DATA IN AFRICA Elvis Karanja MP91 DEVELOPING A PREDICTION MODEL FOR SURVIVAL – A CASE STUDY Samuel Kiliar MP92 DEVELOPMENT OF BLOOD STASIS QUESTIONNAIRE ON GYNECOLOGICAL DISEASES Mi Mi Ko MP93 PERFORMANCE EVALUATION AND IMPROVEMENT OF THE FRAMINGHAM DIABETES RISK MODEL USING COMMUNITY-BASED KOGES DATA Hye Ah Lee MP94 DEVELOPMENT AND VALIDATION OF A PROGNOSTIC MODEL FOR INSTITUTIONALISATION IN PARKSINSONISM: IPD META-ANALYSIS Yan Li MP95 A METHOD FOR PREDICTING CLINICAL TRIAL ENROLLMENT UNDER RESTRICTIVE CONSTRAINTS Dave Lunn Francesca Maher MP96 AN EXTERNAL VALIDATION OF THE KFRE IN CKD PATIENTS OF SOUTH ASIAN ETHNICITY MP97 POPULATION MODELING FOR CIRCANNUAL RHYTHMS OF HBA1C IN TYPE 2 DIABETIC PATIENTS USING LARGE REGISTRY DATA Masako Nishikawa MP98 CURRENT METHODOLOGICAL CHALLENGES IN PROGNOSTIC MODELING - USE CASE MULTIPLE SCLEROSIS Begum Irmak On Juliette ORTHOLAND MP99 LONGITUDINAL AND SURVIVAL JOINT PREDICTION: TIME REPARAMETERIZATION IN AMYOTROPHIC LATERAL SCLEROSIS CONTEXT MP100 INTRODUCING THE 'TETRIS' PLOT FOR VISUALISING THE INSTABILITY IN VARIABLE SELECTION Doug Thompson MP101 TRANSFORMING A PUBLISHED NOMOGRAM BACK TO FORMULAS: HOW TO DO THIS MANUALLY OR WITH AI Junfeng Wang MP102 DYNAMIC PREDICTION BASED ON CONDITIONAL RESTRICTED MEAN SURVIVAL TIME FOR RIGHT-CENSORED DATA Zijing Yang MP103 SEGMENTED REGRESSION IN THE CONTEXT OF KIDNEY FUNCTION AFTER TRANSPLANTATION **Evert Cleenders** MP104 BENCHMARKING AN EMULATED TRIAL AGAINST A REAL TARGET TRIAL: CHALLENGES AND ILLUSTRATION IN CYSTIC FIBROSIS **Emily Granger** MP105 Anita Lindmark EXTENDING INTERVENTIONAL DISPARITY (IN)DIRECT EFFECTS TO INVESTIGATE INEQUALITIES IN ADVERSE STROKE OUTCOME MP106 AGE AND TIME-TRENDS OF THE ASSOCIATION BETWEEN BODY MASS INDEX AND MORTALITY: EVIDENCE FROM THE ODDS STUDY Innocent Mboya MP107 INTEROBSERVER VARIABILITY OF RECALL DECISIONS BETWEEN MAMMOGRAM READERS IN BREAST CANCER SCREENING Laura Quinn MP108 ASSESSING THE EXTERNAL VALIDITY OF THE VALIDATE-SWEDEHEART TRIAL Rebecca Rylance Mohadeseh Shojaei Shahrokhabadi MP109 EXPLORING THE SAMPLE QUALITY: THE COMPARISON OF DATA FROM THE MAPME2 INTERVENTION WITH NCMP, ENGLAND, 2021/22 MP110 HIGH-DIMENSIONAL SELECTION IN A MATCHED CASE-CONTROL STUDY: CARDIOTOXICITY IN CHILDHOOD CANCER SURVIVORS. Naïla Aba MP111 ESTIMATING UNOBSERVED PREVALENCE OF OPIATE AND CRACK USE IN ENGLAND Abdelmajid Djennad amille Giampiccolo MP112 IMPACT OF COMBINED EXPOSURE TO MULTIPLE AIR POLLUTANTS ON BREAST CANCER RISK USING BAYESIAN PROFILE REGRESSION MP113 EFFECT OF BIAS, COMPOSITION, AND DECISION-MAKING IN EXPERT PANELS ON DIAGNOSTIC ACCURACY ESTIMATES MP114 Chiara Casamassima IDENTIFICATION OF CHRONIC PATIENTS WITH ACUTE CHIKUNGUNYA: AN ANALYTICAL METHOD BASED ON AGREEMENT COEFFICIENT Pawin Numthavaj MP115 METASTATIC PROSTATE CANCER TREATMENT: UMBRELLA REVIEW OF SYSTEMATIC REVIEWS AND META-ANALYSES Erica Ponzi MP116 CHALLENGES IN PLANNING AND CONDUCTING EVIDENCE BASED STUDIES IN A PANDEMIC: ARE RCTS REALLY THE GOLD STANDARD? MP117 USING NONLINEAR MODELS TO IDENTIFY BREAKPOINTS IN DISEASE PREVALENCE AMONG PATIENTS WITH MULTIMORBIDITY Roma Puronaitė MP118 COMPARING APPROACHES TO RANK INTERVENTIONS IN A NETWORK META-ANALYSIS: PATIENTS WITH OPIOID DEPENDENCE Myanca Rodrigues MP119 GROUP PENALIZED EXPONENTIAL TILT MODEL FOR DIFFERENTIALLY METHYLATED GENES IN EPIGENETIC ASSOCIATION STUDY Hokeun Sun MP120 CAN WE ESTIMATE A RISK WITHOUT OBSERVING THE RELEVANT NUMBER OF CASES? Toshiro Tango MP121 BAYESIAN BENT-CABLE MODEL FOR LONGITUDINAL AND SURVIVAL TIME WITH HETEROGENOUS RANDOM-EFFECTS Oludare Arivo MP122 DETECTION OF MULTIPLE CHANGE POINTS IN SURVIVAL ANALYSIS WITH NARROWEST SIGNIFICANT PURSUIT TECHNIQUE Samia Ashrafi * MP123 COMPARISON OF METHODS TO ANALYZE TIME-TO-EVENT ENDPOINTS IN TRIALS WITH DELAYED TREATMENT EFFECTS Rouven Behnisch Moritz Fabian Danzer MP124 ADAPTIVE GROUP SEQUENTIAL DESIGNS FOR CLINICAL TRIALS WITH MULTIPLE TIME-TO-EVENT OUTCOMES IN MARKOV MODELS MP125 THE EFFECT OF IMMUNE CORRELATES ON THE PRECISION OF VACCINE EFFICACY EVALUATION: DEMOGRAPHIC SUBGROUPS Julie Dudasova Hiroya Hashimoto MP126 IMPACT OF CENSORING ON ESTIMATION FOR RESTRICTED MEAN SURVIVAL TIME IN SMALL SAMPLE SIZE MP127 RISK FACTORS AND TRANSITIONAL PROBABILITY OF CLINICAL EVENTS IN KOREAN CKD PATIENTS USING THE MULTISTATE MODEL Jinheum Kim MP128 BIAS REDUCTION FOR SEMI-COMPETING RISKS MODEL WITH RARE EVENTS: APPLICATION TO A CHRONIC KIDNEY DISEASE Jayoun Kim MP129 PREVALENCE-INCIDENCE MIXTURE MODEL FOR THE RISK OF HIGH-GRADE CERVICAL LESION BASED ON INDIVIDUAL RISK FACTORS Kelsi Kroon Shun-Fu Lee MP130 COMPARISON OF TOTAL EVENT ANALYSIS IN THREE CARDIOVASCULAR TRIALS WITH COMPOSITE OUTCOMES

* WINNERS OF ISCB CONFERENCE AWARD FOR SCIENTISTS

NON-PARAMETRIC BAYESIAN IMPUTATION OF RIGHT CENSORED DATA IN SURVIVAL ANALYSIS

APPROACHES TO DEAL WITH NON-PROPORTIONAL HAZARDS IN PAEDIATRIC ONCOLOGY - THE CONTEXT MATTERS

ASKING THE RIGHT QUESTION WHEN ASSESSING OS IN TRIALS THAT ALLOW FOR CROSS OVER: CONSIDERATIONS AND CASE STUDY

ADVERSE EVENTS IN TRIALS WITH SURVIVAL OUTCOMES: FROM CLINICAL QUESTIONS TO METHODS FOR STATISTICAL ANALYSIS

TESTING FOR SUFFICIENT FOLLOW-UP TO DETECT THE CURED PROPORTION

Shirin Moghaddam

Alessandro Previtali

Ulrike Pötschgei

Flena Tassistro







Tuesday 28th August 2023

| ID Abstract | TITLE | PRESENTER |
|-------------|--|--------------------------|
| TP1 | METHODS FOR COMBINING DEPENDENT P-VALUES WITH SIDE INFORMATION AND APPLICATION TO GENETICS | Huda Alsulami |
| TP2 | DERIVING INTERPRETABLE THRESHOLDS FOR VARIABLE IMPORTANCE IN RANDOM FORESTS BY PERMUTATION | Maria Blanco |
| TP3 | FAST AND PRECISE SURVIVAL TESTING FOR GENOME-WIDE ASSOCIATION STUDIES | Dominic Edelmann |
| TP4 | HIERARCHICAL NEGATIVE-BINOMIAL MODEL FOR ANALYSIS OF CORRELATED SEQUENCING DATA: PRACTICAL IMPLEMENTATIONS | Katarzyna Górczak |
| TP5 | CONTRIBUTIONS AND CHALLENGES OF DATA FISSION FOR POST-CLUSTERING DIFFERENTIAL ANALYSIS | Benjamin Hivert |
| TP6 | COMPARISON OF STANDARD LINEAR AND RIDGE REGRESSION MODELS USED IN THE SHAPE INDEX CALCULATION | Stanislav Katina |
| TP7 | A STATISTICAL METHODOLOGY TO SELECT AND COMBINE COVARIATES FOR DISEASE CLASSIFICATION IN HIGH-DIMENSIONAL DATA | Claudio Junior Salaroli |
| TP8 | REDUCED VISITS AT EMERGENCY DEPARTMENTS FOR CARDIAC CONDITIONS AND CARDIAC MORTALITY IN THE COVID-19 PANDEMIC | Michalis Katsoulis |
| TP9 | APPLYING MNLFA TO EXAMINE CONSISTENCY IN DSM-5 OPIOID USE DISORDER BETWEEN PAIN PATIENTS AND PEOPLE WHO INJECT | Raimondo Bruno |
| TP10 | DYADIC APPROACHES FOR PATIENT SELF-CARE AND CAREGIVER CONTRIBUTION TO SELF-CARE ASSESSMENT IN TYPE 2 DIABETES | Diletta Fabrizi |
| TP11 | LATENT MARKOV MODEL FOR PROFILING HEART FAILURE PATIENTS' ADHERENCE TO DRUGS | Laura Savaré |
| TP12 | CHALLENGES IN GROUP SEQUENTIAL DESIGNS IN RARE DISEASES | Daniel Bodden |
| TP13 | MULTIPLE REGRESSION MODELS FOR PREDICTING RARE OUTCOMES IN HYPERTROPHIC CARDIOMYOPATHY | Audrone Jakaitiene |
| TP14 | A REVIEW OF THE DESIGN OF CLINICAL TRIALS IN RARE CANCERS | Pallavi Rane |
| TP15 | CLINICAL TRIAL DESIGN AND ESTIMATION METHODS THAT CAN YIELD ADDITIONAL INFORMATION THAN SINGLE-ARM TRIALS | Tomoharu Sato |
| TP16 | THE IMPACT OF ALLOCATION BIAS ON THE TEST DECISIONS IN CLINICAL TRIALS WITH MULTIPLE ENDPOINTS | Stefanie Schoenen |
| TP17 | ADDRESSING BIASES IN ODDS RATIOS FOR RARE CHRONIC SKIN CONDITIONS USING REAL-WORLD PRESCRIPTION DRUG EXPOSURES | Mikolaj Swiderski |
| TP18 | GLOBAL RANK TEST WITH DATA-DRIVEN OPTIMAL WEIGHTS IN CLINICAL TRIALS WITH MULTIPLE ENDPOINTS | SATOSHI YOSHIDA |
| TP19 | THE NON PARAMETRIC COMBINATION METHODOLOGY TO ANALYZE INFLUENCE OF FOOD REGIMES ON OXIDATIVE STRESS PARAMETERS | Angela Alibrandi |
| TP20 | EXPLORING THE MULTIDIMENSIONAL BENEFITS OF A NEW TREATMENT WITH GENERALIZED PAIRWISE COMPARISONS | Emilie Barré |
| TP21 | NONPARAMETRIC COMPARISON OF TWO PROPORTIONS: LE CAM'S THEOREM AND CHERNOFF BOUND APPLIED TO UPPER-LOWER INDEX | Lubomir Stepanek |
| TP22 | IDENTIFICATION OF RISK FACTORS FOR WOUND NON-HEALING: A DESCRIPTIVE STUDY. | Urko Aguirre |
| TP23 | AN EXTENSION OF THE NUMBERS-NEEDED-TO-TREAT CONCEPT BASED ON NET BENEFIT | Alberto Alvarez-Iglesias |
| TP24 | COMPARISON OF SELECTION STRATEGIES TO IDENTIFY BIOSTATISTICAL METHODS - CASE STUDY ON GROUP VARIABLE SELECTION | Gregor Buch |
| TP25 | OPTIMISING SAMPLE ALLOCATION TO BATCHES IN LABORATORY-BASED OBSERVATIONAL STUDIES | Bram Burger |
| TP26 | GENETIC AND ENVIRONMENTAL DETERMINANTS OF DRUG ADHERENCE | Andrea Corbetta |
| TP27 | THE ICH E9(R1) ESTIMAND FRAMEWORK ADAPTED IN A PHASE III EQUIVALENCE RCT CONDUCTED DURING COVID-19 PANDEMIC. | Marian Mitroiu |
| TP28 | ADHERENCE OF SPIRIT GUIDELINES IN NO-PROFIT CLINICAL TRIALS | Giulia Gambini |
| TP29 | A NEW TESTING STRATEGY FOR A TRIAL WITH TWO DOSES COMPARED TO PLACEBO | Philip Hougaard |
| TP30 | FEDERATED ANALYSIS OF MULTIPLE DATA SOURCES | Wilmar Igl |
| TP31 | 3DIV: A COMPREHENSIVE DATABASE OF 3D GENOME AND 3D CANCER GENOME | Insu Jang |
| TP32 | COMPARISON OF ADVERSE EVENT BURDEN BETWEEN TREATMENT GROUPS IN CLINICAL TRIALS USING MIXTURE MODELS | Bartosz Jenner |
| TP33 | A SIMULTANEOUS EVALUATION OF SUPERIORITY AND NON-INFERIORITY FOR COMPARING SCREENING TESTS. | Miyu Kobayashi |
| TP34 | KOREAN NUCLEOTIDE ARCHIVE AS A NEW DATA REPOSITORY FOR NUCLEOTIDE SEQUENCE DATA | JAEHO LEE |
| TP35 | REPLICABILITY OF SIMULATION STUDIES FOR THE INVESTIGATION OF STATISTICAL METHODS: THE REPLISIMS PROJECT | Kim Luijken |
| TP36 | DEALING WITH SPARSE NETWORKS OF INTERVENTIONS: LEARNINGS FROM A SIMULATION STUDY | Hugo Luttenauer |
| TP37 | DIAGNOSTIC NETWORK META-ANALYTIC METHODS FOR PULMONARY EMBOLISM | Eirini Pagkalidou |
| TP38 | GENERALIZED OUTLIER DETECTION FOR SKEWED DISTRIBUTIONS IN BIOMEDICAL SIGNAL | Minsu Park |
| TP39 | PRACTICAL GUIDE ON STATISTICAL ITEMS IN THE NEW SPIRIT-DEFINE EXTENSION FOR EARLY PHASE DOSE-FINDING TRIALS | Jan Rekowski |
| TP40 | SAMPLE SIZE ESTIMATION IN CLINICAL TRIALS USING VENTILATOR-FREE DAYS AS PRIMARY OUTCOME: A SYSTEMATIC REVIEW. | Laurent Renard Triché |
| TP41 | MYOFIBRIL LINEARITY INDEXES IN MUSCLE: A MONTECARLO-BASED ANALYSIS OF PERFORMANCE | Ettore Rocchi |
| TP42 | VARIABILITY IN PRIMARY OUTCOME REPORTING IN CLINICAL TRIALS FOR OLDER ADULTS WITH DEPRESSION | Myanca Rodrigues |
| TP43 | COLLABORATION OPPORTUNITIES ON BIOSTATISTICS WITH EMA | Marcia Rueckbeil |
| TP44 | EVALUATING ZERO-INFLATED MODELS WITH A DIFFERENT BASE DISTRIBUTION IN CLINICAL TRIALS AND MEDICAL RESEARCH | Marzieh Shahmandi |
| TP45 | HYPOTHESIS TESTING PROCEDURE OF F1 SCORES FOR BINARY AND MULTI-CLASS CLASSIFICATION IN THE PAIRED DESIGN | Kanae Takahashi |
| TP46 | FOREIGN BODY INJURIES RECOGNITION AND MANAGEMENT THROUGH TEXT ANALYSIS OF CASE REPORTS | Sara Urru |
| TP47 | ON THE CLUSTER RANDOMISED TRIALS WHERE INTERVENTION EFFECTS ARE HETEROGENEOUS | Kazue Yamaoka |
| TP48 | APPLICATION OF GRAPH THEORY TO INTEGRATE COMPLEX RELATIONSHIPS AMONG HETEROGENEOUS BIOLOGICAL DATA | Byoung-Ha Yoon |
| TP49 | PERFORMANCE COMPARISONS BETWEEN CLUSTERING MODELS FOR RECONSTRUCTING NGS RESULTS FROM TECHNICAL REPLICATES | Yue ZHAI |
| TP50 | TEXT CLASSIFICATION TO AUTOMATE ABSTRACT SCREENING USING MACHINE LEARNING | Samuel Zimmermann |
| TP51 | CONSTRUCTING DNA METHYLATION BIOMARKERS FOR CARDIOVASCULAR DISEASES BY PENALIZED MULTILEVEL MULTITASK LEARNING | Andrea Cappozzo |
| TP52 | RESTRICTED MEAN SURVIVAL TIME PROVIDES INTUITIVE AND ROBUST ABSOLUTE TREATMENT EFFECT ESTIMATES IN RISK STRATA | Carolien Maas |
| TP53 | MULTI-OUTCOME FEATURE SELECTION VIA ANOMALY DETECTION AUTOENCODERS FOR RADIOGENOMIC IN BREAST CANCER PATIENTS | Alessia Mapelli |
| TP54 | A PERSONALIZED ALGORITHM TO DETECT CARDIAC ARRYTHMIA AND MAJOR BLEEDING IN ADVANCED HEART FAILURE PATIENTS | Mehran Moazeni |
| TP55 | PERSONALIZED SCHEDULING OF BIOMARKER MEASUREMENTS FOR HEART FAILURE SURVEILLANCE PROGRAMS WITH COMPETING RISKS | Teun Petersen |
| | | Marika Vezzoli |
| TP56 | THE CLIVUS RECONSTRUCTION: A NOVEL METHOD FOR IDENTIFYING THE OPTIMAL SET OF SCAFFOLDS | IVIGITING VEZZOII |
| TP57 | ENHANCING PATIENT OUTCOMES AND STATISTICAL EFFICIENCY IN RARE-DISEASE PHASE-II TRIALS: THE STRATOSPHERE STUDY | Nina Deliu |







Wednesday 30th August 2023

| ID Abstract | TITLE | PRESENTER |
|--------------|--|---------------------------------------|
| WP1 | IMAGE SEGMENTATION VIA BAYESIAN MIXTURES TO DETECT LATENT SPATIAL PATTERNS IN MASS SPECTROMETRY IMAGING | Giulia Capitoli |
| WP2 | A NOVEL APPROACH TO MODELLING WEIGHTED FMRI NETWORKS USING A BAYESIAN WEIGHTEDEXPONENTIAL RANDOM GRAPH MODEL | Yefeng Fan |
| WP3 | ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION AND RISK OF FALLS: A BAYESIAN NETWORK META-ANALYSIS. | Thibaut Galvain |
| WP4 | RE-ANALYSING FREQUENTIST SYSTEMATIC REVIEWS USING BAYESIAN METHODS | Laura Quinn |
| WP5 | MULTI-INDICATION META-ANALYSIS FOR SHARING OF INFORMATION ON TREATMENT EFFECTIVENESS ACROSS CANCER SUBTYPES | Janharpreet Singh |
| WP6 | RANK-BASED BAYESIAN JOINT VARIABLE SELECTION AND CLUSTERING OF GENOME-WIDE TRANSCRIPTOMIC DATA FROM PAN-CANCER | Valeria Vitelli |
| WP7 WP8 | CIRCULATING EXTRACELLULAR VESICLES AS BIOMARKERS FOR COVID-19 SEVERITY INFLUENCE OF HORMONAL CONTRACEPTIVES ON PLASMA METABOLITE CONCENTRATIONS IN A LARGE COHORT | Miriam Isola Nikola Dordevic |
| WP9 | ASSOCIATION OF SERUM RESISTIN WITH BLOOD STASIS SYNDROME IN KOREAN MEDICINE FOR METABOLIC DISEASES | Mi Mi Ko |
| WP10 | PROGNOSTIC VALUE OF INFLAMMATORY INDEXES IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: RESULTS FROM THE ITA.LI.CA | Vittorio Simeon |
| WP11 | SHOTGUN LIPIDOMICS FOR THE DEVELOPMENT OF A DIAGNOSTIC TEST FOR SCHIZOPHRENIA | Anna Tkachev |
| WP12 | A CALIBRATED SENSITIVITY MODEL FOR OBSERVATIONAL STUDIES WITH MULTIVALUED TREATMENTS | Md. Abdul Basit |
| WP13 | GENETICALLY PROXIED EFFECTS OF PLASMA PROTEINS ON RISK OF MS IDENTIFIED VIA MENDELIAN RANDOMIZATION | Matthew Boyton |
| WP14 | A COMPARISON ON REAL DATA OF METHODS TO DEVELOP INDIVIDUALIZED TREATMENT RULES | Florie Brion Bouvier |
| WP15 WP16 | TRANSPORTING A 'HOSPITAL AT HOME' RCT TREATMENT EFFECT TO A TARGET POPULATION WITH DIFFERING DELIRIUM MEASURES SPASTICITY IN PATIENTS WITH MULTIPLE SCLEROSIS: A BAYESIAN NETWORK APPLICATION | Kate Edgar |
| WP17 | CAUSALOPTIM: A USER-FRIENDLY R-PACKAGE FOR COMPUTATION OF SYMBOLIC SHARP BOUNDS ON COUNTERFACTUAL QUERIES | Teresa Greco Gustav Jonzon |
| WP18 | A NOTE ON THE LATENT UNCONFOUNDEDNESS ASSUMPTION FOR HIERARCHICAL OBSERVATIONAL DATA: A SIMULATION STUDY | Andriana Kostouraki |
| WP19 | TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE COHORT STUDY | Emanuele Koumantakis |
| WP20 | TELL ME WHAT YOU WANT, WHAT YOU REALLY REALLY WANT: ESTIMANDS IN OBSERVATIONAL PHARMACOEPIDEMIOLOGIC STUDIES | Kim Luijken |
| WP21 | HANDLING INFORMATIVE PATIENT MONITORING IN ROUTINELY-COLLECTED DATA USED TO ESTIMATE TREATMENT EFFECTS | Leah Pirondini |
| WP22 | ESTIMATING THE EFFECT OF TREATMENT DELAY: G-COMPUTATION VERSUS CLONE-CENSOR-REWEIGHT APPROACH | Ilaria Prosepe |
| WP23 | SENSITIVITY ANALYSIS WITH MATCHED PAIRS FROM OBSERVATIONAL STUDIES | Priom Saha |
| WP24 | ON CAUSAL INFERENCE FOR THE RELATIVE SURVIVAL SETTING | Matthew Smith |
| WP25 WP26 | MISSING DATA HANDLING AND MODEL-AGNOSTIC TESTS FOR TREATMENT EFFECT HETEROGENEITY IN RANDOMISED TRIALS MULTISTATE MODELS FOR THE ANALYSIS OF TIME-TO-EVENT DATA: THE CASE OF MYELOPROLIFERATIVE NEOPLASMS | Ellie Van Vogt Alessandra Carobbio |
| WP26 | INCREASED CARDIAC RISK AFTER A SECOND MALIGNANT NEOPLASM AMONG CHILDHOOD CANCER SURVIVORS, A FCCSS STUDY | Thibaud Charrier |
| WP28 | A SEMI-PARAMETRIC, NON-PROPORTIONAL COMPETING RISKS MODEL PREDICTING OUTCOMES AFTER KIDNEY TRANSPLANTATION | Maarten Coemans |
| WP29 | ANALYZING DURATION OF RESPONSE IN PHASE II ONCOLOGY TRIALS | Stacy Cyrille |
| WP30 | A MULTI-STATE MODEL EVALUATING THE ASSOCIATION OF OXYGEN THERAPY WITH THE COURSE OF CYSTIC FIBROSIS IN EUROPE | Annalisa Orenti |
| WP31 | GRAPHICAL AND MULTISTATE MODELLING OF HOME DIALYSIS UPTAKE IN PATIENTS WHO NEED KIDNEY REPLACEMENT THERAPY | Ivonne Solis-Trapala |
| WP32 | SGLT2I BETTER SLOW DOWN CHRONIC KIDNEY DISEASE PROGRESSION IN TYPE 2 DIABETES PATIENTS: A MULTISTATE ANALYSIS. | Amarit Tansawet |
| WP33 | SARS-COV-2 TRENDS IN ITALY, GERMANY AND SCHOOL OPENING DURING THE OMICRON VARIANT: A QUASI-EXPERIMENTAL STUDY | Federica Bellerba |
| WP34 WP35 | MENTAL HEALTH OF FAMILY MEMBERS AND FRIENDS OF COVID-19 PATIENTS: AN OBSERVATIONAL COHORT STUDY LIFE EXPECTANCY CHANGES AND COVID-19 VACCINATION CAMPAIGN IMPACT ON ALL-CAUSE MORTALITY IN ITALY | Anikó Lovik |
| WP36 | AGENT-BASED MODELS FOR THE COVID-19 PACCINATION CAMPAIGN INFACT ON ALL-CAOSE MONTACT IN THAT | Andrea Nova Pascal Roy |
| WP37 | A COMBINED CRITERION FOR DOSE FINDING IN PHASE I CLINICAL TRIALS | M. Iftakhar Alam |
| WP38 | HIGH-ORDER ASYMPTOTIC INTERVALS FOR THE TOXICITY PROBABILITY IN PHASE I CLINICAL TRIALS | Abeer Althobety |
| WP39 | BAYESIAN DECISION ANALYSIS FOR CLINICAL TRIAL DESIGN WITH BINARY OUTCOME: ILLUSTRATION FOR EBOLA VIRUS DISEASE | Drifa Belhadi |
| WP40 | OPTIMAL ALLOCATION OF CLUSTERS TO SEQUENCES IN STEPPED WEDGE TRIALS WITH BINARY OUTCOME DATA | Laura Etfer |
| WP41 | TRIAL ESTIMANDS: USING THE COMPOSITE STRATEGY FOR INTERCURRENT EVENTS WHEN THE OUTCOME VARIABLE IS CONTINUOUS | Anneke Grobler |
| WP42 WP43 | EFFICIENT DOSE INSERTION IN PHASE 1 TRIALS: AN ADAPTIVE APPROACH USING MODEL-BASED DESIGN INCORPORATION OF HISTORICAL DATA FOR BASKET TRIALS IN THE EARLY PHASE | Xiaoran Lai |
| WP44 | JOINT MODELING OF PHARMACODYNAMIC BIOMARKER AND SAFETY IN PH1 CLINICAL TRIALS IN ONCOLOGY: SANOFI EXPERIENCE | Wenyue Li Federico Rotolo |
| WP45 | ACTIVE LEVEL SET ESTIMATION IN PHASE I DOSE-FINDING CLINICAL TRIALS | Keiichiro Seno |
| | THE USE OF BASKET TRIALS IN GYNAECOLOGY | Katie Stocking |
| WP47 | WHY DO MENTAL HEALTH TRIALS ONLY ANALYSE A SINGLE PRIMARY OUTCOME? WE CAN DO BETTER. | Dominic Stringer |
| WP48 | ON CONTROLLING THE TYPE I ERROR RATE IN AN INTERRUPTED GROUP SEQUENTIAL TRIAL WITH INTERIM ANALYSES | Amin Yarahmadi |
| WP49 | LONGITUDINAL FUNCTIONAL DATA ANALYSIS WITH APPLICATIONS IN BIOMECHANICS | John Andrew |
| WP50 | GROWTH MIXTURE MODELLING TO IDENTIFY SODIUM PATTERNS. APPLICATION TO ICU DATA IN TRAUMATIC BRAIN INJURY (TBI) | Francesca Graziano |
| WP51 | UNCERTAINTY COMPUTATION AT FINITE DISTANCE IN NONLINEAR MIXED MODELS: EVALUATION OF A NEW BAYESIAN METHOD | Mélanie Guhl |
| WP52 | TIME SERIES ANALYSIS ON HISTORICAL DEATH DATA OF MILAN FROM THE MILAN REGISTERS (1452-1845) | Ester Luconi |
| WP53 | THE EFFICACY OF A MOTIVATIONAL INTERVIEW IN HEART FAILURE PATIENTS AND THEIR CAREGIVERS: A DYADIC ANALYSIS | Giuseppe Occhino |
| WP54 | META-ANALYSIS OF PATIENT-REPORTED OUTCOMES: METHODOLOGICAL PROPOSAL AND APPLICATION TO RCTS IN HEART FAILURE | Chiara Oriecuia |
| WP55 WP56 | MODELING A DISEASE-MODIFYING TREATMENT WITH A PIECEWISE GEODESIC MIXED-EFFECT MODEL SAFETY SIGNAL DETECTION IN BIOCHEMICAL MEASURES IN RANDOMIZED CLINICAL TRIALS, A BAYESIAN MIXED EFFECT MODEL | Pierre-Emmanuel Poulet Alma Revers |
| WP57 | JOINT MODEL FOR MULTIPLE LONGITUDINAL RESPONSES WITH INFORMATIVE TIME MEASUREMENTS | Inês Sousa |
| WP58 | MULTIMODAL PREDICTION OF ECHOCARDIOGRAPHY PRESCRIPTION | Alexandre Bailly |
| WP59 | DIVERSE CONCEPTS OF MACHINE LEARNING ROBUSTNESS IN HEALTHCARE: A SCOPING REVIEW | Alan Balendran |
| WP60 | A PRAGMATIC REGULARIZATION STRATEGY FOR COLLINEARITY-TOLERANT SELECTION OF NONLINEAR RELATIONS | Gregor Buch |
| WP61 | PREDICTING ATTITUDES TOWARDS COVID-19 VACCINATION FOR CHILDREN: A MACHINE LEARNING-BASED APPROACH | Chiara Chiavenna |
| WP62 | BREAST LESION MALIGNANCY PREDICTION USING MACHINE LEARNING AND DEEP LEARNING APPROACHES ON ULTRASOUND IMAGES | Aurora Gaeta |
| WP63 | EVALUATION OF ELIGIBILITY CRITERIA IMPACT ON STUDY OUTCOME AND PATIENT COUNT PREDICTION OF POLYPHARMACY IN HALF A MILLION ADULTS IRANIAN POPULATION: COMPARING MACHINE LEARNING ALGORITHMS | Rana jreich |
| WP64 WP65 | SIGNAL DETECTION IN MEDICAL DEVICES IN SPONTANEOUS REPORTS USING NATURAL LANGUAGE PROCESSING | Naser Kamyari Lan Kelly |
| WP66 | DEEP LEARNING-BASED PREDICTION OF MAJOR ARRHYTHMIC EVENTS IN DILATED CARDIOMYOPATHY | Corrado Lanera |
| | DEMAG PREDICTS THE EFFECTS OF VARIANTS IN ACTIONABLE GENES WITH STRUCTURAL AND EVOLUTIONARY FEATURES | Federica Luppino |
| | | |
| WP67 | | |
| | DETECTION OF RECURRENT CANCER FROM EMR USING NATURAL LANGUAGE PROCESSING: A SYSTEMATIC REVIEW OUTLIER DETECTION FOR TREE-STRUCTURED MODEL IN REGRESSION PROBLEM | Wanchana Ponthongmak Nanaka Seiwa |







Wednesday 30th August 2023

| ID Abstract | TITLE | PRESENTER |
|----------------|--|--|
| WP71 | MACHINE LEARNING REGRESSION MODELS FOR PREDICTING HOSPITAL STAY FOR GENERAL MEDICINE-SPECIFIC PATIENTS | Rossella Miglio |
| WP72 | MISSFOREST V2 – MISSING DATA IMPUTATION FOR PREDICTION SETTINGS | Elena Albu |
| WP73 | EVALUATING BIAS IN CAUSAL MEDIATION EFFECTS WITH NON-ADHERENCE AND MISSING DATA: BETTER SIMULATE THAN NEVER COMPARISON OF IMPUTATION METHODS IN THE PRESENCE OF TIME-VARYING AND NON-LINEAR COVARIATES EFFECTS | Anca Chis Ster Imad EL BADISY |
| WP74 WP75 | SENSITIVITY BOUNDS IN MULTILEVEL MODELING OF LONGITUDINAL DATA WITH DATA MISSING NOT AT RANDOM | Minna Genbäck |
| WP76 | PRACTICAL APPROACH FOR MISSING DATA SENSITIVITY ANALYSES IN JOINT MODELLING OF COGNITION AND DEMENTIA RISK | Tetiana Gorbach |
| WP77 | BAYESIAN LATENT CLASS ANALYSIS CORRECTING FOR VERIFICATION AND REFERENCE STANDARD BIAS IN TB PREVALENCE | Alfred Kipyegon Keter |
| WP78 | THE HANDLING OF MISSING DATA WITH MULTIPLE IMPUTATION IN OBSERVATIONAL STUDIES THAT ADDRESS CAUSAL QUESTIONS | Rheanna Mainzer |
| WP79 | MIN-MAX-MEDIAN/IQR APPROACH. COMPARISON WITH MIN-MAX, LOGISTIC REGRESSION AND XGBOOST. | Rocío Aznar-Gimeno |
| WP80 | MORTALITY PREDICTION: ONE SIZE MAY NOT FIT ALL. THE ITALIAN EXPERIENCE ON THE VALIDITY OF THE PIM 3 SCORE | Rosanna Comoretto |
| WP81 | REPORTING QUALITY OF PROTOCOLS FOR STUDIES DEVELOPING AND VALIDATING A PREDICTION MODEL: A SYSTEMATIC REVIEW | Paula Dhiman |
| WP82 | A SYSTEMATIC REVIEW OF SAMPLE SIZE CALCULATION FOR MACHINE LEARNING PREDICTION MODEL STUDIES IN ONCOLOGY | Paula Dhiman |
| WP83 | BASELINE PREDICTION MODEL OF TIME-TO-FLARE IN RHEUMATOID ARTHRITIS AFTER DMARD CESSATION: THE BIO-FLARE STUDY A SYSTEMATIC REVIEW OF PREDICTION MODELS FOR TRANSITION TO PSYCHOSIS IN INDIVIDUALS MEETING ARMS CRITERIA | Shaun Hiu Alexandra Hunt |
| WP84 WP85 | CLINICAL UTILITY OF PREDICT A PROGNOSTIC TOOL IN BREAST CANCER: DECISION CURVE ANALYSIS | Sadhana Kannan |
| WP86 | BUILDING CENTILE CHARTS OF ECG PARAMETERS IN CHILDREN FROM 0 TO 16 YEARS OLD: AN ITALIAN CROSS-SECTIONAL STUDY | Dariush Khaleghi Hashemian |
| WP87 | UNCERTAINTY QUANTIFICATION IN THE PREDICTIONS OF A EBOLA OUTBREAK USING BAYESIAN DATA ASSIMILATION | Ashok Krishnamurthy |
| WP88 | DO RESEARCHERS CONSIDER THE TIME-DEPENDENT INTERPLAY BETWEEN TIME TO ASSESSMENT AND SEVERITY IN ACUTE STROKE? | Zewen Lu |
| WP89 | INDIVIDUAL TREATMENT EFFECTS OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS ON CHRONIC KIDNEY DISEASE RISK | Thitiya Lukkunaprasit |
| WP90 | PREDICTING NUMBER OF EVENTS USING JOINT MODEL IN CLINICAL TRIALS WITH A TIME-TO-EVENT ENDPOINT | Ryunosuke Machida |
| WP91 | MODEL PREDICTIONS OF THE EFFECTS OF RAPID ART ON HIV AND AIDS | Kazumi Omata |
| WP92 | QUANTIFYING THE ADDED PREDICTIVE VALUE OF PRS IN CVD RISK PREDICTION TOOLS IN INDIVIDUALS WITH MORBIDITY | Carmen Petitjean |
| WP93 | HOW CORRELATIONS BETWEEN MARKERS INFLUENCE THE NET BENEFIT INCREASE OF A PREDICTIVE MODEL | Sergio Sabroso-Lasa |
| WP94 | DEVELOPMENT OF A RISK CALCULATOR AND WEB APPLICATION FOR KIDNEY TRANSPLANTATION WITH R/SHINY IMPACT OF SAMPLE SIZE AND EVENTS PER PREDICTORS ON PERFORMANCE & STABILITY OF PSYCHOSIS RISK PREDICTION MODELS | Simon Schwab Daniel Stahl |
| WP95 WP96 | EVALUATION OF SYSTEMATIC REVIEWS OF PROGNOSTIC MODELS FOR COVID-19: AN OVERVIEW OF SYSTEMATIC REVIEWS. | Persefoni Talimtzi |
| WP97 | EVALUATING CALIBRATION AT MODERATE-STRONG LEVEL USING PATIENT SUBGROUPS IDENTIFIED WITH CLUSTERING ANALYSIS | Junfeng Wang |
| WP98 | ASSESSING THE REPORTING OF IMAGE AND AI BASED CVD DIAGNOSTIC MODELS: EVALUATION AND IMPLEMENTATION OF CLAIM | Junfeng Wang |
| WP99 | THE CHI SQUARE TEST AND THE NEED TO APPLY CORRECTIONS FOR BIG DATA | Calin Avram |
| WP100 | EVALUATION OF THE EFFECTIVENESS OF PCSK9-I IN A TARGET TRIAL EMULATION FRAMEWORK BASED ON EHR | Giulia Barbati |
| WP101 | SPATIAL STATISTICAL MULTILEVEL MODELLING OF OPTIC NERVE DEFORMATION IN MULTIPLE DISEASE GROUPS OF GLAUCOMA | Lauren Coan |
| WP102 | QUANTIFYING THE RISK OF TREATMENT-RELATED ADVERSE EVENTS IN ONCOLOGY: DATA, ISSUES AND MODELS | Elsa COZ |
| WP103 | BALANCE OF TIME-DEPENDENT COVARIATES IN REAL-WORLD DATA VIA THE FRÉCHET DISTANCE | Mireya Diaz |
| WP104 | BIG DATA AND STATISTICAL INFERENCES PROBLEMS: IS EFFECT SIZE MEASURE AN ALTERNATIVE TO P-VALUE? PROJECTIONS OF CARDIOVASCULAR DISEASE DEATHS USING A MICROSIMULATION MODEL IN THE ABSENCE OF COHORT DATA | Arianna Galotta |
| WP105 WP106 | A NEW STATISTICAL INDEX FOR EVALUATING VARIABILITY IN PHYSICAL STATE INDEX DURING PEDIATRIC ANESTHESIA. | Giota Touloumi Cinzia Maria Papappicco |
| WP100 | QUALITY OF LIFE IN PATIENTS AFTER 1-YEAR PERCUTANEOUS CORONARY INTERVENTION: REAL-WORLD DATA ANALYSIS | Sukanya Siriyotha |
| WP108 | "DOING THE DOCTORS WORK" - USEFULNESS OF A SIMPLE PREDICTION MODEL APPLIED TO HEALTH REGISTER DATA IN SWEDEN | Philippe Wagner |
| WP109 | HAVE AIR POLLUTION LEVELS DECREASED MORE IN HIGH INCOME AREAS – A 19-YEAR FOLLOW-UP IN GOTHENBURG, SWEDEN | Eva Andersson |
| WP110 | COMPARISON OF CLINIC VERSUS HOME DEVICES FOR SPIROMETRY ASSESSMENT | Susana Diaz Coto |
| WP111 | SYSTEMATIC MEDIATION ANALYSIS OF GENETIC LOCI ASSOCIATED WITH KIDNEY FUNCTION IN A POPULATION-BASED STUDY | Dariush Ghasemi |
| WP112 | USING AUTOREGRESSION TO MODEL NOVEL VIRAL OUTBREAKS IN HUMAN POPULATIONS TO MANAGE MEDICAL RESOURCES. | Timothy Grant |
| WP113 | PROFILE LIKELIHOOD CONFIDENCE INTERVAL FOR THE PREVALENCE ASSESSED BY AN IMPERFECT DIAGNOSTIC TEST | Péter Hársfalvi |
| WP114 | SENSITIVITY ANALYSIS FOR MULTIPLE EXPOSURE EFFECTS IN GENERALIZED LINEAR MODELS WITH UNMEASURED CONFOUNDERS | Donghwan Lee |
| WP115 | ANALYTIC ERROR IN NATIONAL-LEVEL PREVALENCE SURVEYS OF HEALTHCARE-ASSOCIATED INFECTIONS: A SYSTEMATIC REVIEW CLINICALLY VERSUS CYTOKINE-DEFINED GENITAL INFLAMMATION AND THE RISK OF HIV INFECTION | Evangelos Kritsotakis |
| WP116 WP117 | DIURNAL EATING PATTERNS AND THEIR EFFECT ON BODY MASS INDEX IN THE ITALIAN POPULATION (INRAN-SCAI 2005-2006). | Farzana Osman Luigi Palla |
| WP117 WP118 | LOGISTIC REGRESSION WITH COVARIATE-DEPENDENT PROBABility OF MISCLASSIFICATION | Jenő Reiczigel |
| WP118 WP119 | COMPARISON OF PROPENSITY SCORE METHODS WITH MULTIPLE TREATMENTS: SIMULATIONS AND CLINICAL APPLICATION | Davide Bernasconi |
| WP120 | 30 DAY MORTALITY IN HOSPITALISED COVID-19 PATIENTS: A RETROSPECTIVE STUDY FOR THE PROVINCE OF BOLZANO (ITALY) | Mirko Bonetti |
| WP121 | IMPORTANCE OF SEX-STRATIFICATION IN BIOMARKER IDENTIFICATION OF EARLY-STAGE MELANOMA SURVIVAL ANALYSES | Eirini Chrysanthou |
| WP122 | COMPARISON OF STATISTICAL METHODS FOR SURVIVAL DATA WITH TIME-DEPENDENT COVARIATES AND COMPETING RISKS | Ömer Faruk Dadaş |
| WP123 | ANALYSIS OF TREATMENT OUTCOME IN AN OBSERVATIONAL STUDY IN PEDIATRIC LEUKEMIA WITH A PROPENSITY SCORE APPROACH | Paola De Lorenzo |
| WP124 | ASSESSMENT OF IMPACT ON THE SURVIVAL OUTCOME DUE TO DISCLOSURE OF IMMATURE SURVIVAL DATA IN ONCOLOGY TRIALS | Patrick Djidel |
| WP125 | EFFICIENT ESTIMATION OF THE MARGINAL MEAN OF RECURRENT EVENTS IN RANDOMIZED CLINICAL TRIALS | Luca Genetti |
| WP126 | COMPARISON OF ASYMPTOTIC AND RE-RANDOMIZATION TESTS UNDER NON-PROPORTIONAL HAZARDS SCENARIOS WITH MINIMIZATION | Ryusei Kimura |
| WP127 | STRATIFIED COX MODELS UNDER PARTLY INTERVAL CENSORING THE DEDERDMANCE OF OVERLAD WEIGHTING DE METHOD FOR SURVIVAL ANALYSIS WHEN INTERACTION IN A SURCEOUR EVICT. | Jun Ma |
| WP128 WP129 | THE PERFORMANCE OF OVERLAP WEIGHTING PS METHOD FOR SURVIVAL ANALYSIS WHEN INTERACTION IN A SUBGROUP EXIST EVALUATING SURROGATE ENDPOINTS FOR OVERALL SURVIVAL IN RCTS TESTING IMMUNE CHECKPOINT INHIBITORS | Tomomi Nishikawa Eleonora Pagan |
| WP129 WP130 | OUTCOME PROGNOSTICATION IN ACUTE BRAIN INJURY USING THE NEUROLOGICAL PUPIL INDEX (ORANGE) STUDY. | Matteo Petrosino |
| | IMPACT OF CENSORING MECHANISMS IN ASSESSMENT OF PROGNOSTIC TECHNOLOGIES | Dikshyanta Rana |
| WP131 WP132 | PAIRWISE COX MODELING APPROACH FOR CAUSALLY INTERPRETABLE AVERAGE HAZARD RATIO UNDER NONPROPORTIONAL HAZARDS | Tomohiro Shinozaki |
| WP132 WP133 | JOINT MODELLING OF LONGITUDINAL BIOMARKERS AND OF RISK OF SERIOUS NON-AIDS EVENT IN PEOPLE LIVING WITH HIV | Achilleas Stamoulopoulos |
| WP134 | ADJUSTED KAPLAN-MEIER ESTIMATE FOR PREDICTION OF A DECREASE OF COVID-19 ANTIBODIES BELOW LABORATORY CUT-OFF | Lubomir Stepanek |
| WP135 | ESTIMATION OF THE CUTOFF VALUE FOR CONTINUOUS PROGNOSTIC FACTORS IN SURVIVAL DATA WITH COMPETING RISK | Sook-Young Woo |
| WP136 | CONSTRUCTION OF SURVIVAL TREE BASED ON RESTRICTED MEAN SURVIVAL TIME | Asanao Shimokawa |
| | | 1 |